[go: up one dir, main page]

EP4122537A1 - Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung - Google Patents

Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung Download PDF

Info

Publication number
EP4122537A1
EP4122537A1 EP22179180.9A EP22179180A EP4122537A1 EP 4122537 A1 EP4122537 A1 EP 4122537A1 EP 22179180 A EP22179180 A EP 22179180A EP 4122537 A1 EP4122537 A1 EP 4122537A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
hiv
compound
inhibitors
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22179180.9A
Other languages
English (en)
French (fr)
Inventor
Hang CHU
Ana Z. GONZALEZ BUENROSTRO
Hongyan Guo
Xiaochun Han
Lan Jiang
Jiayao Li
Michael L. Mitchell
Hyung-Jung Pyun
Scott D. Schroeder
Gregg M. SCHWARZWALDER
Nathan D. Shapiro
Devleena M. SHIVAKUMAR
Qiaoyin Wu
Hong Yang
Jennifer R. Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70293100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4122537(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of EP4122537A1 publication Critical patent/EP4122537A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Definitions

  • HIV human immunodeficiency virus
  • Human immunodeficiency virus infection and related diseases are a major public health problem worldwide.
  • Human immunodeficiency virus encodes three enzymes which are required for viral replication: reverse transcriptase, protease, and integrase.
  • reverse transcriptase enzymes which are required for viral replication
  • protease enzymes which are required for viral replication
  • integrase enzymes which are required for viral replication.
  • drugs targeting reverse transcriptase and protease are in wide use and have shown effectiveness, particularly when employed in combination, toxicity and development of resistant strains may limit their usefulness ( Palella, et al. N. Engl. J Med. (1998) 338:853-860 ; Richman, D. D. Nature (2001) 410:995-1001 ). Accordingly, there is a need for new agents that inhibit the replication of HIV.
  • a goal of antiretroviral therapy is to achieve viral suppression in the HIV infected patient.
  • Current treatment guidelines published by the United States Department of Health and Human Services provide that achievement of viral suppression requires the use of combination therapies, i.e ., several drugs from at least two or more drug classes (Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 12, 2019).
  • decisions regarding the treatment of HIV infected patients are complicated when the patient requires treatment for other medical conditions (Id.
  • HIV virus is known to mutate in infected subjects ( Tang, et al. Drugs (2012) 72 (9) e1-e25 ). Because of the proclivity of the HIV virus to mutate, there is a need for anti-HIV drugs to be effective against a range of known HIV variants ( Hurt, et al. HIV/AIDS CID (2014) 58, 423-431 ).
  • Drugs that offer favorable pharmaceutical properties are amenable to less frequent administration and provide for better patient compliance. Such improvements can, in turn, optimize drug exposure and limit the emergence of drug resistance.
  • the present disclosure is directed to novel compounds having antiviral activity and pharmaceutically acceptable salts thereof.
  • the compounds may be used to treat HIV infections, to inhibit the activity of HIV integrase and/or to reduce HIV replication.
  • compounds disclosed herein may be effective against a range of known drug-resistant HIV mutants.
  • compounds disclosed herein may have a decreased propensity to cause drug-drug interactions when co-administered with other drugs.
  • compounds disclosed herein may be administered with less than daily frequency, for example, at weekly, monthly, or longer intervals.
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • kit or an article of manufacture comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and instructions for use.
  • a method of treating an HIV infection in a human having or at risk of having the infection by administering to the human a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of a compound of formula I or a pharmaceutically acceptable salt thereof, is provided.
  • a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of a compound of formula I or a pharmaceutically acceptable salt thereof, for treating an HIV infection in a human having or at risk of having the infection is provided.
  • a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of a compound of formula I or a pharmaceutically acceptable salt thereof, for use in medical therapy is provided.
  • a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of a compound of formula I or a pharmaceutically acceptable salt thereof, for use in treating an HIV infection is provided.
  • a method of using a compound of formula I in therapy is provided.
  • a method of treating the proliferation of the HIV virus, treating AIDS, or delaying the onset of AIDS or ARC symptoms in a mammal comprising administering to the mammal a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, is provided.
  • composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in a method of treating the proliferation of the HIV virus, treating AIDS, or delaying the onset of AIDS or ARC symptoms in a mammal ( e.g ., a human) is provided.
  • kits or an article of manufacture comprising a composition effective to treat or prevent an HIV infection; and packaging material comprising a label which indicates that the composition can be used to treat or prevent infection by HIV.
  • exemplary compositions comprise a compound of formula I as disclosed herein or a pharmaceutically acceptable salt thereof.
  • a method of inhibiting the replication of HIV comprises exposing the virus to an effective amount of a compound of formula I or a salt thereof, under conditions where replication of HIV is inhibited.
  • Amino refers to the -NH 2 radical.
  • C u-v or (C u -C v ) indicates that the following group has from u to v carbon atoms.
  • C 1-6 alkyl indicates that the alkyl group has from 1 to 6 carbon atoms.
  • Alkyl refers to a straight or branched chain hydrocarbon radical consisting of carbon and hydrogen atoms, which is saturated, having from one to twelve carbon atoms (C 1-12 alkyl), in certain embodiments one to eight carbon atoms (C 1-8 alkyl) or one to six carbon atoms (C 1-6 alkyl), or one to four carbon atoms (C 1-4 alkyl), and which is attached to the rest of the molecule by a single bond, e.g ., methyl, ethyl, n -propyl, 1-methylethyl ( iso -propyl), n -butyl, 1-methylpropyl ( sec -butyl), 2-methylpropyl ( iso -butyl), 1,1-dimethylethyl (t-butyl), n -pentyl, hexyl, 3-methylhexyl, 2-methylhexyl, and the like.
  • Alkylene refers to a saturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • an alkylene group can have 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 atoms.
  • Typical alkylene radicals include, but are not limited to, methylene (-CH 2 -), 1,1 ethyl (-CH(CH 3 )-), 1,2-ethyl (-CH 2 CH 2 -), 1,1-propyl (-CH(CH 2 CH 3 )-), 1,2-propyl (-CH 2 CH(CH 3 )-), 1,3-propyl (-CH 2 CH 2 CH 2 -), 1,4-butyl (-CH 2 CH 2 CH 2 CH 2 -), and the like.
  • Aryl or "aromatic ring” refers to an aromatic carbocyclic group having a single ring ( e.g. monocyclic) or multiple rings ( e.g. bicyclic or tricyclic) including fused systems.
  • aryl has 6 to 20 ring carbon atoms ( i.e., C 6-20 aryl), 6 to 12 carbon ring atoms ( i.e., C 6-12 aryl), 6 to 10 carbon ring atoms ( i.e., C 6-10 aryl), or 5 to 10 carbon ring atoms ( i.e., C 5-10 aryl).
  • aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, and anthryl.
  • Carbocyclic ring refers to a non-aromatic hydrocarbon ring consisting of carbon and hydrogen atoms, having from three to fifteen carbon atoms, in certain embodiments having from three to ten carbon atoms or from three to seven carbon atoms, and which is saturated or partially unsaturated and attached to the rest of the molecule by a single bond.
  • Carbocyclic rings include, for example, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene, and cyclooctane.
  • fused refers to a carbocyclic, heterocyclic, aromatic, or heteroaromatic ring structure described herein which is connected to an existing ring structure in the compounds disclosed herein via two adjacent atoms that are shared by the fused ring structure and the existing ring structure.
  • the bicyclic compounds depicted below incorporate fused cyclopropane (i.e., a cyclopropane ring fused to a cyclohexane ring), a fused pyrrolidine (i.e., a pyrrolidine ring fused to a benzene ring), and fused thiophene ( i.e., a thiene ring fused to a furan ring), respectively:
  • Spiro or “spirocyclic” refers to a carbocyclic or heterocyclic ring structure described herein which is connected to an existing ring structure in the compounds disclosed herein via a single atom that is shared by the spiro ring structure and the existing ring structure.
  • the bicyclic compounds below incorporate spiro cyclopropane (i.e., a cyclopropane ring that is spirocyclic to a cyclohexane ring), spiro 1,3-dithiolane (i.e., a 1,3-dithiolane ring that is spirocyclic to a cycloheptane ring), and spiro cyclopentene (i.e., a cyclopentene ring that is spirocyclic to a cyclohexene ring), respectively:
  • Halo or halogen refers to bromo, chloro, fluoro or iodo.
  • Haloalkyl refers to an alkyl group, as defined above, that is substituted by one or more halo radicals, as defined above, e.g ., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
  • Heteroaromatic ring refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms (for example, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom) independently selected from nitrogen, oxygen, and sulfur.
  • heteroaryl includes 5 to 20 ring atoms (5 to 20 membered heteroaromatic ring), 5 to 12 ring atoms (5 to 12 membered heteroaromatic ring), 5 to 10 ring atoms (5 to 10 membered heteroaromatic ring) or 5 to 6 ring atoms (5 to 6 membered heteroaromatic ring).
  • Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl.
  • Heterocyclyl or “heterocyclic ring” refers to a non-aromatic radical or ring having from three to fifteen atoms wherein from one to six atoms are heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and attached to the rest of the molecule by a single bond.
  • heterocyclyl has from three to ten atoms, wherein from one to four atoms are heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, or from three to seven atoms, wherein from one to two atoms are heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • heterocyclyl or “heterocyclic ring” refers to rings that are saturated unless otherwise indicated, e.g., in some embodiments “heterocyclyl” or “heterocyclic ring” refers to rings that are saturated or partially saturated where specified.
  • heterocyclyl examples include, but are not limited to, dioxolanyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
  • these radiolabeled compounds are useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action.
  • Certain isotopically-labeled compounds of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa, or XIb are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e., 3 H, and carbon-14, i.e., 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • substitution with heavier isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability. For example, in vivo half-life may increase or dosage requirements may be reduced. Thus, heavier isotopes may be preferred in some circumstances.
  • Isotopically-labeled compounds of formula I can be prepared by techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • the methods, compositions, kits and articles of manufacture provided herein use or include compounds (e.g ., a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa, or XIb) or pharmaceutically acceptable salts thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule.
  • the deuterium atom is a non-radioactive isotope of the hydrogen atom.
  • Such compounds increase resistance to metabolism, and thus are useful for increasing the half-life of compounds or pharmaceutically acceptable salts thereof, when administered to a mammal. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984 ).
  • Such compounds can be synthesized by means known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
  • the embodiments disclosed herein are also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the embodiments disclosed herein include compounds produced by a process comprising administering a compound according to the embodiments disclosed herein to a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products are typically identified by administering a radiolabeled compound according to the embodiments disclosed herein in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
  • “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and nondomestic animals such as wildlife and the like.
  • Optional or “optionally” means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
  • optionally substituted heterocyclyl means that the heterocyclyl radical may or may not be substituted and that the description includes both substituted heterocyclyl radicals and heterocyclyl radicals having no substitution.
  • “Pharmaceutically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, emulsifier, or other pharmacologically inactive substance that is formulated in combination with a pharmacologically active ingredient of a pharmaceutical composition and is compatible with the other ingredients of the formulation and suitable for use in humans or domestic animals without undue toxicity, irritation, allergic response, and the like.
  • salts derived from an appropriate base such as an alkali metal (for example, sodium), an alkaline earth metal (for example, magnesium), ammonium and NX 4 + (wherein X is C 1-4 alkyl).
  • salts of a nitrogen atom or an amino group include, for example, salts of organic carboxylic acids such as acetic, trifluoroacetic, adipic, ascorbic, aspartic, butyric, camphoric, cinnamic, citric, digluconic, glutamic, glycolic, glycerophosphoric, formic, hexanoic, benzoic, lactic, fumaric, tartaric, maleic, hydroxymaleic, malonic, malic, mandelic, isethionic, lactobionic, nicotinic, oxalic, pamoic, pectinic, phenylacetic, 3-phenylpropionic, pivalic, propionic, pyruvic, salicylic, stearic, sulfanilic, tartaric, undecanoic, and succinic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, camphors,
  • salts of active ingredients of the compounds disclosed herein will typically be pharmaceutically acceptable, i.e., they will be salts derived from a physiologically acceptable acid or base.
  • salts of acids or bases which are not pharmaceutically acceptable may also find use, for example, in the preparation or purification of a compound of formula I or another compound of the embodiments disclosed herein. All salts, whether or not derived from a physiologically acceptable acid or base, are within the scope of the embodiments disclosed herein.
  • Metal salts typically are prepared by reacting the metal hydroxide with a compound according to the embodiments disclosed herein.
  • metal salts which are prepared in this way are salts containing Li + , Na + , and K + .
  • a less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound.
  • compositions herein comprise compounds disclosed herein in their un-ionized, as well as zwitterionic form.
  • a “pharmaceutical composition” refers to a formulation of a compound of the embodiments disclosed herein and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable excipients.
  • Effective amount refers to an amount of a compound according to the embodiments disclosed herein, which when administered to a patient in need thereof, is sufficient to effect treatment of disease-states, conditions, or disorders disclosed herein. Such an amount would be sufficient to elicit the biological or medical response of a tissue system, or patient that is sought by a researcher or clinician.
  • the amount of a compound according to the embodiments disclosed herein which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of the treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination, or coincidentally, with the compounds of the embodiments disclosed herein, and the age, body weight, general health, sex and diet of the patient.
  • a therapeutically effective amount can be determined by one of ordinary skill in the art having regard to their own knowledge, the state of the art, and this disclosure.
  • treating and “treatment” as used herein are intended to mean the administration of a compound or composition according to the present embodiments disclosed herein to alleviate or eliminate one or more symptoms of HIV infection and/or to reduce viral load in a patient.
  • the terms “treating” and “treatment” also encompass the administration of a compound or composition according to the present embodiments disclosed herein post-exposure of the individual to the virus but before the appearance of symptoms of the disease, and/or prior to the detection of the virus in the blood, to prevent the appearance of symptoms of the disease and/or to prevent the virus from reaching detectable levels in the blood, and the administration of a compound or composition according to the present embodiments disclosed herein to prevent perinatal transmission of HIV from mother to baby, by administration to the mother before giving birth and to the child within the first days of life.
  • treating and “treatment” also encompass the administration of a compound or composition according to the present embodiments disclosed herein before the exposure of the individual to the virus (also called pre-exposure prophylaxis or PrEP), to prevent HIV infection from taking hold if the individual is exposed to the virus and/or to keep the virus from establishing a permanent infection and/or to prevent the appearance of symptoms of the disease and/or to prevent the virus from reaching detectable levels in the blood.
  • PrEP pre-exposure prophylaxis
  • the terms “treating” and “treatment” also encompass the administration of a compound or composition according to the present embodiments disclosed herein both before and after the exposure of the individual to the virus.
  • the terms “preventing” and “prevention” refer to the administration of a compound, composition, or pharmaceutically salt according to the present disclosure pre- or post-exposure of the human to the virus but before the appearance of symptoms of the disease, and/or prior to the detection of the virus in the blood.
  • the terms also refer to prevention of the appearance of symptoms of the disease and/or to prevent the virus from reaching detectible levels in the blood.
  • the terms include both pre-exposure prophylaxis (PrEP), as well as post-exposure prophylaxis (PEP) and event driven or "on demand” prophylaxis.
  • PrEP pre-exposure prophylaxis
  • PEP post-exposure prophylaxis
  • event driven or "on demand” prophylaxis event driven or "on demand prophylaxis.
  • the terms also refer to prevention of perinatal transmission of HIV from mother to baby, by administration to the mother before giving birth and to the child within the first days of life.
  • the terms also refer to prevention of transmission of HIV through blood
  • antiviral agent as used herein is intended to mean an agent (compound or biological) that is effective to inhibit the formation and/or replication of a virus in a human being, including but not limited to agents that interfere with either host or viral mechanisms necessary for the formation and/or replication of a virus in a human being.
  • inhibitor of HIV replication is intended to mean an agent capable of reducing or eliminating the ability of HIV to replicate in a host cell, whether in vitro, ex vivo or in vivo.
  • the compounds of the embodiments disclosed herein, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
  • the present disclosure is meant to include all such possible isomers, as well as their racemic, scalemic, and optically pure forms.
  • Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using methods such as chromatography and fractional crystallization.
  • Techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
  • HPLC high pressure liquid chromatography
  • stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.
  • compounds disclosed herein may be in the form of a stereoisomer thereof.
  • Partially unsaturated refers to a cyclic group which contains at least one double bond but is not aromatic.
  • compositions comprising such compounds optionally in combination with one or more (e.g., two, three, or four) additional therapeutic agents, and methods of using such compounds and compositions.
  • All compound embodiments described herein include any pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof.
  • a compound of the following formula (I) is provided: or a pharmaceutically acceptable salt thereof, wherein
  • R 2 is H, C 1-4 alkyl, or C 1-4 haloalkyl. In some embodiments, R 2 is H or C 1-4 alkyl. In some embodiments, R 2 is H. In some embodiments, R 2 is C 1-4 alkyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is H or methyl. In some embodiments, R 2 is C 1-4 haloalkyl.
  • R 2 is selected from the group consisting of H, -CH 3 , - CH 2 CH 3 , and -CH 2 F, or R 2 and R 8b together with the carbon to which they are attached form a 3-membered fused carbocyclic ring.
  • R 2 is selected from the group consisting of H, -CH 3 , -CH 2 CH 3 , and -CH 2 F.
  • R 2 and R 8b together with the carbon to which they are attached form a 3-membered fused carbocyclic ring.
  • Y is -C(O)NH-. In some embodiments, Y is Q. In some embodiments, Y is
  • the compound of formula I is a compound of formula (II): or a pharmaceutically acceptable salt thereof, wherein R 1 , L, W 1 , W 2 , X, and Z are as defined in formula I.
  • R 1 is H. In some embodiments, R 1 is C 6-10 aryl. In some embodiments, R 1 is phenyl, optionally substituted with one to four R A1 , wherein each R A1 is independently halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, -O-C 1-4 alkyl, or C 1-4 alkyl-O-C 1-4 alkyl. In some embodiments, R 1 is phenyl substituted with one, two, three, or four R A1 . In some embodiments, R 1 is phenyl substituted with one, two, three, or four R A1 .
  • R 1 is phenyl substituted with one, two, three, or four R A1 , wherein each R A1 is independently halo, C 1-4 alkyl, C 1-4 haloalkyl, or -O-C 1-4 alkyl. In some embodiments, R 1 is phenyl substituted with one, two, three, or four R A1 , wherein each R A1 is independently halo, C 1-4 alkyl, or C 1-4 haloalkyl. In some embodiments, R 1 is phenyl substituted with one, two, three, or four R A1 , wherein each R A1 is independently halo or -O-C 1-4 alkyl.
  • R 1 is phenyl substituted with one, two, three, or four halogens. In some embodiments, R 1 is phenyl substituted with one, two, or three halogens. In some embodiments, R 1 is phenyl substituted with two or three halogens. In some embodiments, R 1 is phenyl substituted with two or three halogens selected from chloro and fluoro. In some embodiments, R 1 is
  • R 1 is selected from the group consisting of In some embodiments, of the compound of formula I or II, R 1 is selected from the group consisting of and In some embodiments, R 1 is selected from the group consisting of and
  • L is -CR 3a R 3b -, wherein R 3a and R 3b are independently H, C 1-4 alkyl, C 1-6 haloalkyl, C(O)R c , or SO 2 R c .
  • L is -CR 3a R 3b -, wherein R 3a and R 3b are independently H or C 1-4 alkyl.
  • L is -CH 2 -.
  • L is - CH(CH 3 )-.
  • L is -C(O)-.
  • L is or -CH 2 -CH 2 -.
  • L is -CH 2 -, -CH(CH 3 )-, -C(O)-, or -CH 2 -CH 2 -.
  • L is -N(R a )-.
  • the compound of formula I or II is a compound of formula: or a pharmaceutically acceptable salt thereof, wherein R 1 , L, W 1 , W 2 , X, and Z are as defined in formula I.
  • the compound of formula I or II is a compound of formula (IV): or a pharmaceutically acceptable salt thereof, wherein R 1 , W 1 , W 2 , X, and Z are as defined in formula I.
  • the compound of formula I, II, or IV is a compound of formula: or a pharmaceutically acceptable salt thereof, wherein R 1 , W 1 , W 2 , X, and Z are as defined in formula I.
  • the compound of formula I or II is a compound of formula (VI):
  • the compound of formula I, II, or VI is a compound of formula: or a pharmaceutically acceptable salt thereof, wherein R 1 , W 1 , W 2 , X, and Z are as defined in formula I.
  • W 1 is a bond.
  • W 1 is -CR 4a R4 b -.
  • W 1 is -CR 4a R 4b -, wherein R 4a and R 4b are independently H or halo.
  • W 1 is -CH 2 -.
  • W 1 is -CF 2 -.
  • W 1 is -CH(F)-.
  • W 1 is a bond, -CH 2 -, - CF 2 - or -CH(F)-.
  • W 1 is a bond or -CH 2 -.
  • W 1 is a bond or -CR 4a R 4b -, wherein each R 4a and R 4b is independently H, halo, or C 1-6 alkyl.
  • W 1 is bond or -CR 4a R 4b -, wherein each R 4a and R 4b is independently H, halo, or -CH 3 .
  • W 1 is bond, -CH 2 -, -CH(F)-, CF 2 , -CH(CH 3 )- or -CF(CH 3 )-.
  • W 2 is -CR 5a R 5b -. In some embodiments, W 2 is -CR 5a R 5b -, wherein R 5a and R 5b are independently H, C 1-4 alkyl, C 1-4 haloalkyl, halo, hydroxyl, cyano, -O-C 1-4 alkyl, or C 1-4 alkylene-O-C 1-4 alkyl. In some embodiments, W 2 is -CR 5a R 5b -, wherein R 5a and R 5b are independently H, C 1-4 alkyl, C 1-4 haloalkyl, halo, or hydroxyl.
  • W 2 is -CR 5a R 5b -, wherein R 5a and R 5b are independently H or halo. In some embodiments, W 2 is -CH 2 -. In some embodiments, W 2 is - CF 2 -. In some embodiments, W 2 is -CH(F)-. In some embodiments, W 2 is -CR 5a R 5b -CR 5c R 5d -.
  • W 2 is -CR 5a R 5b -CR 5c R 5d -, wherein R 5a , R 5b , R 5c , and R 5d are independently H, C 1-4 alkyl, C 1-4 haloalkyl, halo, hydroxyl, cyano, -O-C 1-4 alkyl, or C 1-4 alkylene-O-C 1-4 alkyl.
  • W 2 is -CR 5a R 5b -CR 5c R 5d -, wherein R 5a , R 5b , R 5c , and R 5d are independently H, C 1-4 alkyl, C 1-4 haloalkyl, halo, hydroxyl.
  • W 2 is - CR 5a R 5b -CR 5c R 5d -, wherein R 5a , R 5b , R 5c , and R 5d are independently H or halo. In some embodiments, W 2 is -CH 2 CH 2 -.
  • W 2 is -CR 5a R 5b -CR 5c R 5d -, wherein R 5a and R 5c are independently H or halo and R 5b and R 5d together with the carbon atoms to which each is attached form a 3- to 7-membered saturated or partially unsaturated fused carbocyclic ring, optionally substituted with one to three R A3 , wherein each R A3 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • W 2 is -CR 5a R 5b -CR 5c R 5d -, wherein R 5a and R 5c are independently H or halo and R 5b and R 5d together with the carbon atoms to which each is attached form a 3- to 5-membered saturated fused carbocyclic ring.
  • W 2 is -CHR 5b -CHR 5d -, wherein R 5b and R 5d together with the carbon atoms to which each is attached form a 3-, 4-, or 5-membered saturated fused carbocyclic ring.
  • W 2 is wherein p is 0, 1, 2, 3, or 4. In some embodiments, W 2 is wherein each R A4 is independently halo. In some embodiments, W 2 is wherein each R A4 is independently halo and p is 0, 1, 2, or 3. In some embodiments, W 2 is wherein each R A4 is independently halo and p is 0, 1, or 2. In some embodiments, W 2 is In some embodiments, W 2 is In some embodiments, W 2 is -N(R 7 )-. In some embodiments, W 2 is -N(R 7 )-, wherein R 7 is H, C 1-4 alkyl, C 1-4 haloalkyl, C(O)R c , or SO 2 R c .
  • W 2 is -N(R 7 )-, wherein R 7 is H, C 1-4 alkyl, C(O)R c , or SO 2 R c .
  • W 2 is -NH-.
  • W 2 is - N(CH 3 )-.
  • W 2 is -N(CH(CH 3 ) 2 )-.
  • W 2 is - N(C(O)R c )-.
  • W 2 is -N(C(O)CH 3 )-.
  • W 2 is - N(SO 2 R c )-.
  • W 2 is -N(SO 2 CH 3 )-.
  • W 2 is -O-. In some embodiments, W 2 is -CR 5a R 5b -N(R 7 )-. In some embodiments, W 2 is -CH 2 -N(R 7 )-. In some embodiments, W 2 is-CR 5a R 5b -O-. In some embodiments, W 2 is or -CH 2 -O-.
  • the compound of formula I, II, IIIa, IIIb, IV, Va, or Vb has a formula (X):
  • the compound of formula I, II, IIIa, IIIb, IV, Va, or Vb has a formula (Xa):
  • the compound of formula I, II, IIIa, IIIb, IV, Va, or Vb has a formula (Xb):
  • the compound of formula I, II, IIIa, IIIb, IV, Va, or Vb has a formula (XI):
  • the compound of formula I, II, IIIa, IIIb, IV, Va, Vb or X has a formula (XIa):
  • the compound of formula I, II, IIIa, IIIb, IV, Va, Vb or X has a formula (XIb):
  • X is bond or -CR 8a R 8b -; wherein R 8a and R 8b are each independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkylene-O-C 1-4 alkyl, C 1-6 alkyl, C 1-4 haloalkyl, cyano, or halo.
  • R 8a and R 8b are each independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkylene-O-C 1-4 alkyl, C 1-6 alkyl, C 1-4 haloalkyl, cyano, or halo.
  • X is bond.
  • X is-CR 8a R 8b -; wherein R 8a and R 8b are each independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkylene-O-C 1-4 alkyl, C 1-6 alkyl, C 1-4 haloalkyl, cyano, or halo.
  • X is-CR 8a R 8b -; wherein R 8a and R 8b are each independently H, C 1-6 alkyl, C 1-4 haloalkyl, or halo.
  • R 8a and R 8b are each independently H, -CH 3 , -CHF 2 , -CH 2 F, or halo.
  • Z is -CR 9a R 9b - or -CR 9a R 9b CR 9c R 9d -; wherein R 9a , R 9b , R 9c , and R 9d are each independently H, C 1-6 alkyl, or C 1-4 haloalkyl.
  • Z is -CR 9a R 9b -.
  • Z is -CR 9a R 9b CR 9c R 9d -.
  • R 9a , R 9b , R 9c , and R 9d are each independently H, -CH 3 , -CHF 2 , or -CH 2 F.
  • each R 6a and R 6b is independently H, halo, C 1-4 haloalkyl, or C 1-6 alkyl.
  • each R 5a , R 5b , R 5c , and R 5d is independently H, halo, C 1-4 haloalkyl, or C 1-6 alkyl.
  • X is a bond.
  • X is -CR 8a R 8b -.
  • X is -CR 8a R 8b -, wherein R 8a and R 8b are independently H, hydroxyl, C 1-4 alkyl, or halo.
  • X is - CR 8a R 8b -, wherein R 8a is H, fluoro, or hydroxyl and R 8b is H or fluoro.
  • X is -CH 2 -. In some embodiments, X is -CF 2 -. In some embodiments, X is -CH(F)-. In some embodiments, X is -CH(OH)-. In some embodiments, X is -CH(CH 3 )-. In some embodiments, X is -CF(CH 3 )-. In some embodiments, X is -CH 2 -, -CF 2 -, -CH(F)-, -CH(OH)-, -CH(CH 3 ) or -CF(CH 3 )-.
  • X is -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form a 3-, 4-, or 5-membered saturated spiro ring containing 0 to 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • X is -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form a 3- to 5-membered saturated spiro ring containing 0 heteroatoms, wherein the spiro ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • X is -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form an spiro cyclopropane ring.
  • X is a bond or -CR 8a R 8b -, wherein R 8a and R 8b are independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkyl, C 1-4 haloalkyl, or halo, or wherein R 8a and R 8b together with the carbon to which they are attached form a 3 to 5-membered saturated spiro ring containing 0 to 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • X is a bond or -CR 8a R 8b -, wherein R 8a and R 8b are independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkyl, C 1-4 haloalkyl, or halo, or wherein R 8a and R 8b together with the carbon to which they are attached form a 3 to 5-membered saturated spiro heterocyclic ring containing 1 or 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • X is a bond or -CR 8a R 8b -, wherein R 8a and R 8b are independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkyl, C 1-4 haloalkyl, or halo, or wherein R 8a and R 8b together with the carbon to which they are attached form a 3 to 5-membered saturated spiro heterocyclic ring containing 1 or 2 heteroatoms selected from N, O, and S.
  • X is a bond or -CR 8a R 8b -, wherein R 8a and R 8b are independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkyl, C 1-4 haloalkyl, or halo, or wherein R 8a and R 8b together with the carbon to which they are attached form a 3-5 membered saturated spiro carbocyclic ring, wherein the a 3-5 membered saturated spiro carbocyclic ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • X is a bond or - CR 8a R 8b -, wherein R 8a and R 8b are independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkyl, C 1-4 haloalkyl, or halo, or wherein R 8a and R 8b together with the carbon to which they are attached form a 3-5 membered saturated spiro carbocyclic ring.
  • X is a bond or -CR 8a R 8b -, wherein R 8a and R 8b are independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkyl, C 1-4 haloalkyl, or halo, or wherein R 8a and R 8b together with the carbon to which they are attached form a 3-membered saturated spiro carbocyclic ring, wherein the 3 membered saturated spiro carbocyclic ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • X is a bond or -CR 8a R 8b -, wherein R 8a and R 8b are independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkyl, C 1-4 haloalkyl, or halo, or wherein R 8a and R 8b together with the carbon to which they are attached form a 3-membered saturated spiro carbocyclic ring.
  • X is a bond, -CH 2 -, -CF 2 -, -CH(F)-, -CH(Cl)-, -CH(OH)-, -C(CH 2 F)(OH)-, -C(CH 3 )(OH)-, - CH(OCH 3 )-, -C(CH 2 CH 3 )(OCH 3 )-, -C(CH 2 CH 3 )(OH)-, -CH(CH 3 )-, -CH(CH 2 CH 3 )-, -CF(CH 3 )-, -CF(CH 2 CH 3 )-, or -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon
  • X is a bond, -CH 2 -, -CF 2 -, -CH(F)-, -CH(Cl)-, -CH(OH)-, -C(CH 2 F)(OH)-, - C(CH 3 )(OH)-, -CH(OCH 3 )-, -C(CH 2 CH 3 )(OCH 3 )-, -C(CH 2 CH 3 )(OH)-, -CH(CH 3 )-, - CH(CH 2 CH 3 )-, -CF(CH 3 )-, or -CF(CH 2 CH 3 ).
  • X is a bond, -CH 2 -, -CF 2 -, -CH(F)-, -CH(Cl)-, -CH(OH)-, -C(CH 2 F)(OH)-, -C(CH 3 )(OH)-, -CH(OCH 3 )-, -C(CH 2 CH 3 )(OCH 3 )-, -C(CH 2 CH 3 )(OH)-, - CH(CH 3 )-, -CH(CH 2 CH 3 )-, -CF(CH 3 )-, -CF(CH 2 CH 3 )-, -C(CH 2 F)(H)-, or -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form a 3-membered saturated spiro carbocyclic ring.
  • X is a bond, -CH 2 -, -CF 2 -, -CH(F)-, - CH(Cl)-, -CH(OH)-, -C(CH 2 F)(OH)-, -C(CH 3 )(OH)-, -CH(OCH 3 )-, -C(CH 2 CH 3 )(OCH 3 )-, - C(CH 2 CH 3 )(OH)-, -CH(CH 3 )-, -CH(CH 2 CH 3 )-, -CF(CH 3 )-, -C(CH 2 F)(H)-, or- CF(CH 2 CH 3 )-.
  • X is - CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form a 3 to 5-membered saturated spiro ring containing 0 to 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalky.
  • X is -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form a 3-5 membered saturated spiro carbocyclic ring, wherein the a 3-5 membered saturated spiro carbocyclic ring optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • X is -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form a 3-membered spiro carbocyclic ring.
  • X is -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form a 3 to 5-membered saturated spiro heterocyclic ring containing 1 or 2 heteroatoms selected from N, O, and S, wherein the a 3 to 5-membered saturated spiro heterocyclic ring optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl. In some embodiments.
  • X is -CR 8a R 8b -, wherein R 8a and R 8b together with the carbon to which they are attached form a 3 to 5-membered saturated spiro heterocyclic ring containing 1 or 2 heteroatoms selected from N, O, and S.
  • the compound of formula I or II is a compound of formula (VIII) : or a pharmaceutically acceptable salt thereof, wherein R 1 , L, W 1 , W 2 , and Z are as defined in formula I .
  • Z is -CR 9a R 9b -.
  • Z is -CR 9a R 9b -, wherein R 9a and R 9b are independently H, C 1-4 alkyl, C 1-4 haloalkyl, or halo.
  • Z is -CR 9a R 9b -, wherein R 9a and R 9b are independently H or C 1-4 alkyl.
  • Z is -CH 2 -.
  • Z is wherein q is 0, 1, 2, 3, or 4.
  • Z is wherein each R A4 is independently halo.
  • Z is wherein each R A4 is independently halo and q is 0, 1, 2, or 3.
  • Z is wherein each R A4 is independently halo and q is 0, 1, or 2.
  • Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some embodiments, Z is In some
  • L is -CR 3a R 3b - and R 3a and R 3b are independently H, C 1-4 alkyl, C 1-4 haloalkyl, or -O-C 1-4 alkyl.
  • R 3a and R 3b are independently H or C 1-4 alkyl.
  • R 3a and R 3b are H.
  • R 3a and R 3b are C 1-4 alkyl.
  • R 3a is H and R 3b is C 1-4 alkyl.
  • R 3a is H and R 3b is methyl.
  • R 3a and R 3b together with the carbon atom to which they are attached form a 3- to 7-membered saturated or partially unsaturated spiro ring containing 0 to 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to three R A2 , wherein each R A2 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 3a and R 3b together with the carbon atom to which they are attached form a 3-, 4-, or 5-membered saturated or partially unsaturated spiro ring containing 0 to 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to three R A2 , wherein each R A2 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 3a and R 3b together with the carbon atom to which they are attached form a 3- or 4-membered saturated spiro ring containing 0 heteroatoms or 1 heteroatom selected from N, O, and S, wherein the spiro ring is optionally substituted with one to three R A2 , wherein each R A2 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 3a and R 3b together with the carbon atom to which they are attached form a 3-membered saturated spiro ring containing 0 heteroatoms or 1 heteroatom selected from N, O, and S, wherein the spiro ring is optionally substituted with one to three R A2 , wherein each R A2 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 3a and R 3b together with the carbon atom to which they are attached form a spiro cyclopropane ring.
  • W 1 is -CR 4a R 4b - and R 4a and R 4b are independently H, C 1-4 alkyl, C 1-4 haloalkyl, or halo.
  • R 4a and R 4b are independently H or halo.
  • R 4a and R 4b are H.
  • R 4a and R 4b are halo.
  • R 4a and R 4b are fluoro.
  • R 4a is H and R 4b is halo.
  • R 4a is H and R 4b is fluoro.
  • W 2 is -CR 5a R 5b - and R 5a and R 5b are independently H, C 1-4 alkyl, C 1-4 haloalkyl, halo, hydroxyl, cyano, -O-C 1-4 alkyl, or C 1-4 alkylene-O-C 1-4 alkyl.
  • R 5a and R 5b are independently H, C 1-4 alkyl, C 1-4 haloalkyl, halo, or hydroxyl. In some embodiments, R 5a and R 5b are independently H or halo. In some embodiments, R 5a and R 5b are H. In some embodiment, R 5a and R 5b are halo. In some embodiments, R 5a and R 5b are fluoro. In some embodiments, R 5a is H and R 5b is halo. In some embodiments, R 5a is H and R 5b is fluoro.
  • R 5a and R 5b together with the carbon atom to which they are attached form a 3- to 7-membered saturated or partially unsaturated spiro ring containing 0 to 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to three R A3 , wherein each R A3 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 5a and R 5b together with the carbon atom to which they are attached form a 3-, 4-, or 5-membered saturated or partially unsaturated spiro ring containing 0 to 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to three R A3 , wherein each R A3 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 5a and R 5b together with the carbon atom to which they are attached form a 3- or 4-membered saturated spiro ring containing 0 heteroatoms or 1 heteroatom selected from N, O, and S, wherein the spiro ring is optionally substituted with one to three R A3 , wherein each R A3 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 5a and R 5b together with the carbon atom to which they are attached form a 3-membered saturated spiro ring containing 0 heteroatoms or 1 heteroatom selected from N, O, and S, wherein the spiro ring is optionally substituted with one to three R A3 , wherein each R A3 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 5a and R 5b together with the carbon atom to which they are attached form a spiro cyclopropane ring.
  • W 2 is -CR 5a R 5b CR 5c R 5d - and R 5a , R 5b , R 5c , and R 5d are independently H, C 1-4 alkyl, C 1-4 haloalkyl, halo, hydroxyl, cyano, -O-C 1-4 alkyl, or C 1-4 alkylene-O-C 1-4 alkyl.
  • R 5a , R 5b , R 5c , and R 5d are independently H, C 1-4 alkyl, C 1-4 haloalkyl, halo, or hydroxyl. In some embodiments, R 5a , R 5b , R 5c , and R 5d are independently H or halo. In some embodiments, R 5a , R 5b , R 5c , and R 5d are H.
  • R 5a and R 5c are independently H or halo and R 5b and R 5d together with the carbon atoms to which each is attached form a 3- to 7-membered saturated or partially unsaturated fused carbocyclic ring, optionally substituted with one to three R A3 , wherein each R A3 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 5a and R 5c are independently H or halo and R 5b and R 5d together with the carbon atoms to which each is attached form a 3-, 4-, or 5-membered saturated fused carbocyclic ring.
  • R 5a and R 5c are H and R 5b and R 5d together with the carbon atoms to which each is attached form a 3-, 4-,or 5-membered saturated fused carbocyclic ring. In some embodiments, R 5a and R 5c are H and R 5b and R 5d together with the carbon atoms to which each is attached form a fused cyclopropane ring.
  • R 6a and R 6b together with the atoms to which each is attached form a 5- to 10-membered fused aromatic ring, optionally substituted with one to four R A4 , wherein each R A4 is independently halo or C 1-4 alkyl.
  • R 6a and R 6b together with the atoms to which each is attached form a fused 1,2-phenylene ring, optionally substituted with one to four R A4 , wherein each R A4 is independently halo or C 1-4 alkyl.
  • R 6a and R 6b together with the atoms to which each is attached form wherein p is 0, 1, 2, 3, or 4.
  • R 6a and R 6b together with the atoms to which each is attached form wherein each R A4 is independently halo. In some embodiments, R 6a and R 6b together with the atoms to which each is attached form wherein each R A4 is independently halo and p is 0, 1, 2, or 3. In some embodiments, R 6a and R 6b together with the atoms to which each is attached form wherein each R A4 is independently halo and p is 0, 1, or 2. In some embodiments, R 6a and R 6b together with the atoms to which each is attached form In some embodiments, R 6a and R 6b together with the atoms to which each is attached form
  • W 2 is -N(R 7 )- and R 7 is H, C 1-4 alkyl, C 1-4 haloalkyl, C(O)R c , or SO 2 R c .
  • R 7 is H, C 1-4 alkyl, C(O)R c , or SO 2 R c .
  • R 7 is H.
  • R 7 is C 1-4 alkyl.
  • R 7 is methyl or 1-methylethyl. In some embodiments, R 7 is C(O)R c . In some embodiments, R 7 is -C(O)-C 1-4 alkyl. In some embodiments, R 7 is -C(O)CH 3 . In some embodiments, R 7 is SO 2 R c . In some embodiments, R 7 is -SO 2 -C 1-4 alkyl. In some embodiments, R 7 is -SO 2 CH 3 .
  • X is -CR 8a R 8b - and R 8a and R 8b are independently H, hydroxyl, -O-C 1-4 alkyl, C 1-4 alkylene-O-C 1-4 alkyl, C 1-4 alkyl, C 1-4 haloalkyl, cyano, or halo.
  • R 8a and R 8b are independently H, hydroxyl, C 1-4 alkyl, or halo.
  • R 8a is H, fluoro, or hydroxyl and R 8b is H or fluoro. In some embodiments, R 8a and R 8b are H. In some embodiments, R 8a and R 8b are fluoro. In some embodiments, R 8a is H and R 8b is halo. In some embodiments, R 8a is H and R 8b is fluoro. In some embodiments, R 8a is H and R 8b is hydroxyl. In some embodiments, R 8a is H and R 8b is C 1-4 alkyl. In some embodiments, R 8a is H and R 8b is methyl. In some embodiments, R 8a is halo and R 8b is C 1-4 alkyl.
  • R 8a is fluoro and R 8b is methyl.
  • R 8a and R 8b together with the carbon to which they are attached form a 3-, 4-, or 5-membered saturated spiro ring containing 0 to 2 heteroatoms selected from N, O, and S, wherein the spiro ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 8a and R 8b together with the carbon to which they are attached form a 3-, 4-, or 5-membered saturated spiro ring containing 0 heteroatoms, wherein the spiro ring is optionally substituted with one to four R A5 , wherein each R A5 is independently halo, C 1-4 alkyl or C 1-4 haloalkyl.
  • R 8a and R 8b together with the carbon to which they are attached form an spiro cyclopropane ring.
  • Z is -CR 9a R 9b - and R 9a and R 9b are independently H, C 1-4 alkyl, C 1-4 haloalkyl, or halo.
  • R 9a and R 9b are independently H or C 1-4 alkyl.
  • R 9a and R 9b are H.
  • R 9a and R 9b are C 1-4 alkyl.
  • R 9a is H and R 9b is C 1-4 alkyl.
  • R 9a is H and R 9b is methyl.
  • Z is -CR 9a R 9b -CR 9c R 9d - and R 9a , R 9b , R 9c , and R 9d are independently H, C 1-4 alkyl, C 1-4 haloalkyl, or halo. In some embodiments, R 9a , R 9b , R 9c , and R 9d are independently H or C 1-4 alkyl. In some embodiments, R 9a , R 9b , R 9c , and R 9d are H.
  • R 10a and R 10b together with the atoms to which each is attached form a 5- to 10-membered fused aromatic ring or heteroaromatic ring containing 1 to 2 heteroatoms selected from N, O and S, wherein the aromatic or heteroaromatic ring is optionally substituted with one to four R A7 , wherein each R A7 is independently halo or C 1-4 alkyl.
  • R 10a and R 10b together with the atoms to which each is attached form a 5- to 10-membered fused aromatic ring, optionally substituted with one to four R A7 , wherein each R A7 is independently halo or C 1-4 alkyl.
  • R 10a and R 10b together with the atoms to which each is attached form a fused 1,2-phenylene ring, optionally substituted with one to four R A7 , wherein each R A7 is independently halo or C 1-4 alkyl.
  • R 10a and R 10b together with the atoms to which each is attached form wherein q is 0, 1, 2, 3, or 4.
  • R 10a and R 10b together with the atoms to which each is attached form wherein each R A4 is independently halo.
  • R 10a and R 10b together with the atoms to which each is attached form wherein each R A4 is independently halo and q is 0, 1, 2, or 3.
  • R 10a and R 10b together with the atoms to which each is attached form wherein each R A4 is independently halo and q is 0, 1, or 2. In some embodiments, R 10a and R 10b together with the atoms to which each is attached form In some embodiments, R 10a and R 10b together with the atoms to which each is attached form In some embodiments, R 10a and R 10b together with the atoms to which each is attached form
  • R a is independently H, C 1-4 alkyl, C 1-6 haloalkyl, C(O)R c , or SO 2 R c .
  • R b is H. In some embodiments, R b is C 1-4 alkyl. In some embodiments, R b is methyl.
  • R c is C 1-4 alkyl. In some embodiments, R c is methyl. In some embodiments, R c is -O-C 1-4 alkyl.
  • n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI , VIIa , VIIb , or VIII is a compound of formula (IX): or a pharmaceutically acceptable salt thereof, wherein R 1 is H or C 6-10 aryl, wherein C 6-10 aryl is optionally substituted with one to four R A1 , wherein each R A1 is independently halo, C 1-6 alkyl, C 1-4 haloalkyl, cyano, -O-C 1-4 alkyl, or C 1-4 alkyl-O-C 1-4 alkyl.
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII , or IX is a compound of formula (IXa):
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI , VIIa , VIIb , VIII, or IX is a compound of formula (IXb): or a pharmaceutically acceptable salt thereof, wherein R 1 is H or C 6-10 aryl, wherein C 6-10 aryl is optionally substituted with one to four R A1 , wherein each R A1 is independently halo, C 1-6 alkyl, C 1-4 haloalkyl, cyano, -O-C 1-4 alkyl, or C 1-4 alkyl-O-C 1-4 alkyl.
  • R 1 is H. In some embodiments, R 1 is C 6-10 aryl.
  • R 1 is phenyl, optionally substituted with one to four R A1 , wherein each R A1 is independently halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, -O-C 1-4 alkyl, or C 1-4 alkyl-O-C 1-4 alkyl. In some embodiments, R 1 is phenyl substituted with one, two, three, or four R A1 . In some embodiments, R 1 is phenyl substituted with one, two, three, or four R A1 .
  • R 1 is phenyl substituted with one, two, three, or four R A1 , wherein each R A1 is independently halo, C 1-4 alkyl, C 1-4 haloalkyl, or -O-C 1-4 alkyl. In some embodiments, R 1 is phenyl substituted with one, two, three, or four R A1 , wherein each R A1 is independently halo, C 1-4 alkyl, or C 1-4 haloalkyl. In some embodiments, R 1 is phenyl substituted with one, two, three, or four R A1 , wherein each R A1 is independently halo or -O-C 1-4 alkyl.
  • R 1 is phenyl substituted with one, two, three, or four halogens. In some embodiments, R 1 is phenyl substituted with one, two, or three halogens. In some embodiments, R 1 is phenyl substituted with two or three halogens. In some embodiments, R 1 is phenyl substituted with two or three halogens selected from chloro and fluoro. In some embodiments, R 1 is
  • R 1 is selected from the group consisting of In some embodiments, of the compound of formula I or II , R 1 is selected from the group consisting of and
  • the compounds have the formula:
  • the compounds have the formula:
  • the compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI , VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa, or XIb is selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
  • the compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI , VIIa , VIIb , VIII, IX, IXa, or IXb , X, Xa, Xb, XI, XIa , or XIb , is selected from the group consisting of: and and or a pharmaceutically acceptable salt thereof.
  • the compounds of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX , IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , may be described with reference to rings A, B, and C, as depicted below for formula I: where A denotes a bridged ring relative to ring B, B denotes a bridged ring relative to ring A and a fused ring relative to ring C, and C denotes a fused ring relative to ring B.
  • the compounds may have one or more additional fused or spirocyclic rings.
  • both orientations of the group are intended to be covered, unless specified otherwise.
  • W 2 is -CR 5a R 5b -N(R 7 )-
  • both orientations of -CR 5a R 5b -N(R 7 )- are included ( i.e., both Z-W 1 -CR 5a R 5b -N(R 7 )-X and Z-W 1 -N(R 7 )-CR 5a R 5b -X are included)
  • Z is both orientations of are included (i.e., both are included).
  • compositions comprising a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient are provided.
  • the pharmaceutical compositions further comprise one, two, three, or four additional therapeutic agents.
  • the additional therapeutic agent or agents are anti-HIV agents.
  • the additional therapeutic agent or agents are HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV capsid inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, latency reversing agents, capsid polymerization inhibitors, HIV bNAbs, TLR7 agonists, pharmacokinetic enhancers, other drugs for treating HIV, or combinations thereof.
  • the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, N-(( S )-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1 H- indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-l-yn-l-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3b S ,4a R )-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1 H- cyclopropa[3,4]cyclopenta[1,2- c ]pyrazol-1-yl)acetamide, or a pharmaceutically acceptable salt thereof.
  • the present disclosure relates to a kit comprising a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof.
  • the kit may comprise one, two, three, or four additional therapeutic agents as described hereinbefore.
  • the kit may further comprise instructions for use, e.g., for use in inhibiting an HIV integrase, such as for use in treating an HIV infection or AIDS, or as a research tool.
  • the instructions for use are generally written instructions, although electronic storage media ( e . g ., magnetic diskette or optical disk) containing instructions are also acceptable.
  • the present disclosure also relates to a pharmaceutical kit comprising one or more containers comprising a compound formula I, II, IIIa, IIIb, IV, Va , Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical kit comprising one or more containers comprising a compound formula I, II, IIIa, IIIb, IV, Va , Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical kit comprising one or more containers comprising a compound formula I, II, IIIa, IIIb, IV, Va , Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X,
  • kits may be in unit dosage forms, bulk packages (e . g ., multi-dose packages) or sub-unit doses. Kits may also include multiple unit doses of the compounds and instructions for use and be packaged in quantities sufficient for storage and use in pharmacies ( e . g ., hospital pharmacies and compounding pharmacies).
  • articles of manufacture comprising a unit dosage of a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa , IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, in suitable packaging for use in the methods described herein.
  • suitable packaging is known in the art and includes, for example, vials, vessels, ampules, bottles, jars, flexible packaging and the like.
  • An article of manufacture may further be sterilized and/or sealed.
  • the methods further comprise administering to the human a therapeutically effective amount of one, two, three, or four additional therapeutic agents.
  • the additional therapeutic agent or agents are anti-HIV agents.
  • the additional therapeutic agent or agents are HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV capsid inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, latency reversing agents, capsid polymerization inhibitors, HIV bNAbs (broadly neutralizing HIV antibodies), TLR7 agonists, pharmacokinetic enhancers, other drugs for treating HIV, or combinations thereof.
  • the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, N-(( S )-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1 H -indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3b S ,4a R )-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1 H -cyclopropa[3,4]cyclopenta[1,2- c ]pyrazol-l-yl)acetamide, or a pharmaceutically acceptable salt thereof.
  • a use of a compound of formula I, II, IIIa, IIIb, IV, Va, Vb , VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of a compound of formula I, II , IIIa , IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, for treating an HIV (e.g., HIV-1 and/or HIV-2) infection in a human having or at risk of having the infection is provided.
  • an HIV e.g., HIV-1 and/or HIV-2
  • a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI , VIIa , VIIb , VIII, IX, IXa , IXb , X, Xa, Xb, XI , XIa , or XIb , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI , VIIa , VIIb , VIII, IX, IXa, IXb, X, Xa, Xb, XI , XIa , or XIb , or a pharmaceutically acceptable salt thereof, for use in medical therapy is provided.
  • a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or pharmaceutically acceptable salt thereof, for use in treating an HIV infection is provided.
  • the one, two, three, or four additional therapeutic agents are selected from HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, latency reversing agents, HIV capsid inhibitors, HIV bNAbs, TLR7 agonists, and combinations thereof.
  • a method of using a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , in therapy is provided.
  • a method of treating the proliferation of the HIV virus, treating AIDS, or delaying the onset of AIDS or ARC symptoms in a mammal e .
  • a human comprising administering to the mammal a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • a composition comprising a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in a method of treating the proliferation of the HIV virus, treating AIDS, or delaying the onset of AIDS or ARC symptoms in a mammal ( e . g ., a human) is provided.
  • PrEP pre-expo
  • a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating an HIV infection in a human being having or at risk of having the infection is disclosed.
  • a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, as a research tool is disclosed.
  • an article of manufacture comprising a composition effective to treat an HIV infection; and packaging material comprising a label which indicates that the composition can be used to treat infection by HIV is disclosed.
  • exemplary compositions comprise a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof.
  • a method of inhibiting the replication of HIV comprises exposing the virus to an effective amount of the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a salt thereof, under conditions where replication of HIV is inhibited.
  • a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , to inhibit the activity of the HIV integrase enzyme is disclosed.
  • a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI , XIa , or XIb , or a salt thereof, to inhibit the replication of HIV is disclosed.
  • the compounds described herein are administered as a raw chemical or are formulated as pharmaceutical compositions.
  • Pharmaceutical compositions within the scope of the embodiments disclosed herein comprise a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX , IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , and a pharmaceutically acceptable excipient.
  • the compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI , XIa , or XIb is present in the composition in an amount which is effective to treat a particular disease or condition of interest.
  • the activity of compounds of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb can be determined as described in the Examples below.
  • compositions of the embodiments disclosed herein can be prepared by combining a compound of the embodiments disclosed herein with an appropriate pharmaceutically acceptable excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols.
  • compositions of the embodiments disclosed herein are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient.
  • Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the embodiments disclosed herein in aerosol form may hold a plurality of dosage units.
  • composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the embodiments disclosed herein, or a pharmaceutically acceptable salt thereof, for treating a disease or condition of interest in accordance with the teachings of this disclosure.
  • the pharmaceutical composition is an oral dosage unit. In one embodiment, the pharmaceutical composition is a solid oral dosage unit. In one embodiment, the pharmaceutical composition is a tablet.
  • the pharmaceutical composition is a parenteral dosage unit. In one embodiment, the pharmaceutical composition is a subcutaneous, intramuscular, intravenous, intradermal, intrathecal, or epidural dosage unit. In one embodiment, the pharmaceutical composition is a subcutaneous, intramuscular, or intravenous dosage unit. In one embodiment, the pharmaceutical composition is injectable.
  • compositions disclosed herein may be prepared by methodology well known in the pharmaceutical art.
  • a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the embodiments disclosed herein with sterile, distilled water so as to form a solution.
  • a surfactant may be added to facilitate the formation of a homogeneous solution or suspension.
  • Surfactants are compounds that non-covalently interact with the compound of the embodiments disclosed herein so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
  • the compounds of the embodiments disclosed herein, or their pharmaceutically acceptable salts are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.
  • a method for treating an HIV infection in a human having or at risk of having the infection comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one, two, three, or four additional therapeutic agents.
  • a method for treating an HIV infection in a human having or at risk of having the infection comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one, two, three, or four additional therapeutic agents.
  • compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one, two, three, or four additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent, or excipient are provided.
  • the present disclosure provides a method for treating an HIV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one, two, three, or four additional therapeutic agents which are suitable for treating an HIV infection.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with one, two, three, four, or more additional therapeutic agents. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents.
  • the one, two, three, four, or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.
  • a compound disclosed herein is administered with one, two, three, or four additional therapeutic agents.
  • Co-administration of a compound disclosed herein with one, two, three, or four additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one, two, three, or four additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and the one, two, three, or four additional therapeutic agents are both present in the body of the patient.
  • the combination may be administered in two or more administrations.
  • Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one, two, three, or four additional therapeutic agents.
  • the compound disclosed herein may be administered within seconds, minutes, or hours of the administration of the one, two, three, or four additional therapeutic agents.
  • a unit dose of a compound disclosed herein is administered first, followed within seconds or minutes by administration of a unit dose of one, two, three, or four additional therapeutic agents.
  • a unit dose of one, two, three, or four additional therapeutic agents is administered first, followed by administration of a unit dose of a compound disclosed herein within seconds or minutes.
  • a unit dose of a compound disclosed herein is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one, two, three, or four additional therapeutic agents.
  • a unit dose of one, two, three, or four additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound disclosed herein.
  • a compound disclosed herein is combined with one, two, three, or four additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
  • kits comprising a compound disclosed herein (e.g., a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb ,), or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, or four) additional therapeutic agents is provided.
  • a compound disclosed herein e.g., a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb ,
  • one or more e.g., one, two, three, or four
  • a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI , VIIa , VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb is formulated as a tablet, which may optionally contain one or more other compounds useful for treating HIV.
  • the tablet can contain another active ingredient for treating HIV, such as HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, pharmacokinetic enhancers, and combinations thereof.
  • HIV protease inhibitors HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase
  • HIV nucleoside or nucleotide inhibitors of reverse transcriptase HIV integrase inhibitors
  • HIV non-catalytic site (or allosteric) integrase inhibitors HIV non-catalytic site (or allosteric) integrase inhibitors
  • pharmacokinetic enhancers pharmacokinetic enhancers, and combinations thereof.
  • such tablets are suitable for once daily dosing.
  • the additional therapeutic agent or agents may be an anti-HIV agent, selected from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T-cell, CAR-T, and engineered T cell receptors, TCR-T, autologous T cell therapies), latency reversing agents, compounds that target the HIV capsid, capsid polymerization inhibitors, HIV bNAbs, immune-based
  • the additional therapeutic agent or agents are selected from combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, and bispecific antibodies, and "antibody-like" therapeutic proteins, and combinations thereof.
  • combination drugs include ATRIPLA ® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA ® (EVIPLERA ® ; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD ® (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA ® (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY ® (tenofovir alafenamide and emtricitabine); ODEFSEY ® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA ® (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); SYM
  • Examples of other drugs for treating HIV include acemannan, alisporivir, BanLec, deferiprone, Gamimune, metenkefalin, naltrexone, Prolastin, REP 9, RPI-MN, VSSP, H1viral, SB-728-T, 1,5-dicaffeoylquinic acid, rHIV7-shl-TAR-CCR5RZ, MazF gene therapy, BlockAide, ABX-464, AG-1105, APH-0812, BIT-225, CYT-107, HGTV-43, HPH-116, HS-10234, IMO-3100, IND-02, MK-1376, MK-2048, MK-4250, MK-8507, MK-8591, NOV-205, PA-1050040 (PA-040), PGN-007, SCY-635, SB-9200, SCB-719, TR-452, TEV-90110, TEV-90112, TEV-90111, TEV-90113
  • HIV protease inhibitors include amprenavir, atazanavir, brecanavir, darunavir, fosamprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, tipranavir, DG-17, TMB-657 (PPL-100), T-169, BL-008, MK-8122, TMB-607, and TMC-310911.
  • HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase include dapivirine, delavirdine, delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan, nevirapine, rilpivirine, ACC-007, AIC-292, KM-023, PC-1005, and elsulfavirine (VM-1500).
  • HIV nucleoside or nucleotide inhibitors of reverse transcriptase examples include adefovir, adefovir dipivoxil, azvudine, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, VIDEX ® and VIDEX EC ® (didanosine, ddl), abacavir, abacavir sulfate, alovudine, apricitabine, censavudine, didanosine, elvucitabine, festinavir, fosalvudine tidoxil, CMX-157, dapivirine, doravirine, e
  • HIV integrase inhibitors include elvitegravir, curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, raltegravir, dolutegravir, JTK-351, bictegravir, AVX-15567, diketo quinolin-4-1 derivatives, integrase-LEDGF inhibitor, ledgins, M-522, M-532, NSC-310217, NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172
  • NICKI HIV non-catalytic site, or allosteric, integrase inhibitors
  • HIV entry (fusion) inhibitors examples include cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 attachment inhibitors, gp120 inhibitors, and CXCR4 inhibitors.
  • CCR5 inhibitors examples include aplaviroc, vicriviroc, maraviroc, cenicriviroc, leronlimab (PRO-140), adaptavir (RAP-101), nifeviroc (TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, and vMIP (Haimipu).
  • gp41 inhibitors examples include albuvirtide, enfuvirtide, BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, PIE-12 trimer and sifuvirtide.
  • CD4 attachment inhibitors examples include ibalizumab and CADA analogs.
  • gp120 inhibitors examples include Radha-108 (receptol) 3B3-PE38, BanLec, bentonite-based nanomedicine, fostemsavir tromethamine, IQP-0831, and BMS-663068.
  • CXCR4 inhibitors examples include plerixafor, ALT-1188, N15 peptide, and vMIP (Haimipu).
  • HIV maturation inhibitors examples include BMS-955176, GSK-3640254 and GSK-2838232.
  • latency reversing agents examples include histone deacetylase (HDAC) inhibitors, proteasome inhibitors such as velcade, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, ionomycin, PMA, SAHA (suberanilohydroxamic acid, or suberoyl, anilide, and hydroxamic acid), IL-15 modulating antibodies, JQ1, disulfiram, amphotericin B, and ubiquitin inhibitors such as largazole analogs, APH-0812, GSK-343, and toll-like receptor modulators.
  • HDAC histone deacetylase
  • proteasome inhibitors such as velcade
  • PKC protein kinase C
  • Smyd2 inhibitors Smyd2 inhibitors
  • BET-bromodomain 4 (BRD4) inhibitors ionomycin
  • PMA protein kinase C
  • SAHA sube
  • HDAC inhibitors examples include romidepsin, vorinostat, and panobinostat.
  • PKC activators examples include indolactam, prostratin, ingenol B, and DAG-lactones.
  • capsid inhibitors examples include capsid polymerization inhibitors or capsid disrupting compounds, HIV nucleocapsid p7 (NCp7) inhibitors such as azodicarbonamide, HIV p24 capsid protein inhibitors, GS-6207, AVI-621, AVI-101, AVI-201, AVI-301, and AVI-CAN1-15 series.
  • NCp7 HIV nucleocapsid p7
  • immune-based therapies include toll-like receptors modulators such as TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13; programmed cell death protein 1 (Pd-1) modulators; programmed death-ligand 1 (PDL-1) modulators; IL-15 modulators; DermaVir; interleukin-7; plaquenil (hydroxychloroquine); proleukin (aldesleukin, IL-2); interferon alfa; interferon alfa-2b; interferon alfa-n3; pegylated interferon alfa; interferon gamma; hydroxyurea; mycophenolate mofetil (MPA) and its ester derivative mycophenolate mofetil (MMF); ribavirin; polymer polyethyleneimine (PEI); gepon; IL-12; WF-10; VGV-1; MOR-22; BMS-936559; CYT
  • TLR agonists examples include vesatolimod (GS-9620), lefitolimod, tilsotolimod, rintatolimod, DSP-0509, AL-034, G-100, cobitolimod, AST-008, motolimod, GSK-1795091, GSK-2245035, VTX-1463, GS-9688, LHC-165, BDB-001, RG-7854, and telratolimod.
  • PI3K inhibitors include idelalisib, alpelisib, buparlisib, CAI orotate, copanlisib, duvelisib, gedatolisib, neratinib, panulisib, perifosine, pictilisib, pilaralisib, puquitinib mesylate, rigosertib, rigosertib sodium, sonolisib, taselisib, AMG-319, AZD-8186, BAY-1082439, CLR-1401, CLR-457, CUDC-907, DS-7423, EN-3342, GSK-2126458, GSK-2269577, GSK-2636771, INCB-040093, LY-3023414, MLN-1117, PQR-309, RG-7666, RP-6530, RV-1729, SAR-245409, SAR-260301, SF-1126
  • Integrin alpha-4/beta-7 antagonists include PTG-100, TRK-170, abrilumab, etrolizumab, carotegrast methyl, and vedolizumab.
  • HIV antibodies, bispecific antibodies, and "antibody-like" therapeutic proteins include DARTs ® , DUOBODIES ® , BITES ® , XmAbs ® , TandAbs ® , Fab derivatives, bispecific antibodies, trispecific antibodies, multivalent antibodies, bNAbs (broadly neutralizing HIV antibodies), BMS-936559, TMB-360, and those targeting HIV gp120 or gp41, antibody-recruiting Molecules targeting HIV, anti-CD63 monoclonal antibodies, CD3 bispecific antibodies, CD16 bispecific antibodies, anti-GB virus C antibodies, anti-GP120/CD4, CCR5 bispecific antibodies, anti-Nef single domain antibodies, anti-Rev antibody, camelid derived anti-CD18 antibodies, camelid-derived anti-ICAM-1 antibodies, DCVax-001, gp140 targeted antibodies, gp41-based HIV therapeutic antibodies, human recombinant mAbs (PGT-121), ibalizumab
  • Examples of those targeting HIV in such a manner include bavituximab, UB-421, C2F5, 2G12, C4E10, C2F5+C2G12+C4E10, 8ANC195, 3BNC117, 3BNC117-LS, 3BNC60, 10-1074, 10-1074-LS, GS-9722, DH411-2, PGT145, PGT121, PGT-151, PGT-133, MDX010 (ipilimumab), DH511, N6, N6LS, N49P6, N49P7, N49P9, N49P11, VRC01 VRC-01-LS, PGDM1400, A32, 7B2, 10E8, 10E8VLS, 3810109, 10E8v4, CAP256-VRC26.25, DRVIA7, SAR-441236, VRC-07-523, VRC07-523LS, VRC-HIVMAB080-00-AB, VRC-HIVMAB060-00-AB, P2G12
  • Example of in vivo delivered bNAbs such as AAV8-VRC07; mRNA encoding anti-HIV antibody VRC01.
  • Examples of pharmacokinetic enhancers include cobicistat and ritonavir.
  • Examples of additional therapeutic agents include the compounds disclosed in WO 2004/096286 (Gilead Sciences ), WO 2006/015261 (Gilead Sciences ), WO 2006/110157 (Gilead Sciences ), WO 2012/003497 (Gilead Sciences ), WO 2012/003498 (Gilead Sciences ), WO 2012/145728 (Gilead Sciences ), WO 2013/006738 (Gilead Sciences ), WO 2013/159064 (Gilead Sciences ), WO 2014/100323 (Gilead Sciences ), US 2013/0165489 (University of Pennsylvania ), US 2014/0221378 (Japan Tobacco ), US 2014/0221380 (Japan Tobacco ), WO 2009/062285 (Boehringer Ingelheim ), WO 2010/130034 (Boehringer Ingelheim ), WO 2013/006792 (Pharma Resources ), US 20140221356 (Gilead Sciences ), US 20100143301 (
  • HIV vaccines include peptide vaccines, recombinant subunit protein vaccines, live vector vaccines, DNA vaccines, CD4-derived peptide vaccines, vaccine combinations, rgp120 (AIDSVAX), ALVAC HIV (vCP1521)/AIDSVAX B/E (gp120) (RV144), monomeric gp120 HIV subtype C vaccine, Remune, ITV-1, Contre Vir, Ad5-ENVA-48, DCVax-001 (CDX-2401), Vacc-4x, Vacc-C5, VAC-3S, multiclade DNA recombinant adenovirus-5 (rAd5), rAd5 gag-pol env A/B/C vaccine, Pennvax-G, Pennvax-G/MVA-CMDR, HIV-TriMix-mRNA vaccine, HIV-LAMP-vax, Ad35, Ad35-GRIN, NAcGM3/VSSP ISA-51, poly-ICLC adjuvanted vaccines, TatImmune, GTU-multi
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with one, two, three, four or more additional therapeutic agents selected from ATRIPLA ® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA ® (EVIPLERA ® ; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD ® (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA ® (tenofovir disoproxil fumarate and emtricitabine; TDF +FTC); DESCOVY ® (tenofovir alafenamide and emtricitabine); ODEFSEY ® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA ® (ten
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with at least one HIV nucleoside inhibitor of reverse transcriptase, an integrase inhibitor, and a pharmacokinetic enhancer.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with two HIV nucleoside or nucleotide inhibitors of reverse transcriptase.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV capsid inhibitor or an HIV capsid polymerization inhibitor.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV capsid inhibitor or an HIV capsid polymerization inhibitor.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with one, two, three or four HIV bNAbs.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with one, two, three or four HIV bNAbs and a HIV capsid inhibitor or an HIV capsid polymerization inhibitor.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with one, two, three or four HIV bNAbs, an HIV capsid inhibitor or an HIV capsid polymerization inhibitor, and an HIV nucleoside or nucleotide inhibitor of reverse transcriptase.
  • a compound as disclosed herein may be combined with one, two, three, or four additional therapeutic agents in any dosage amount of the compound of formula I (e.g., from 1 mg to 500 mg of compound).
  • kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents are provided.
  • the additional therapeutic agent or agents of the kit is an anti-HIV agent, selected from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T-cell, CAR-T, and engineered T cell receptors, TCR-T, autologous T cell therapies), compounds that target the HIV capsid, latency reversing agents, capsid polymerization inhibitors, HIV bNAbs, immune-based
  • the additional therapeutic agent or agents of the kit are selected from combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, and bispecific antibodies, and "antibody-like" therapeutic proteins, and combinations thereof.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and an HIV nucleoside or nucleotide inhibitor of reverse transcriptase.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, at least one HIV nucleoside inhibitor of reverse transcriptase, an integrase inhibitor, and a pharmacokinetic enhancer.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and two HIV nucleoside or nucleotide inhibitors of reverse transcriptase.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV capsid inhibitor or an HIV capsid polymerization inhibitor.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and an HIV capsid inhibitor or an HIV capsid polymerization inhibitor.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and one, two, three or four HIV bNAbs.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, one, two, three or four HIV bNAbs and a HIV capsid inhibitor or an HIV capsid polymerization inhibitor.
  • the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, one, two, three or four HIV bNAbs, an HIV capsid inhibitor or an HIV capsid polymerization inhibitor, and an HIV nucleoside or nucleotide inhibitor of reverse transcriptase.
  • Therapeutic agents used for birth control include cyproterone acetate, desogestrel, dienogest, drospirenone, estradiol valerate, ethinyl estradiol, ethynodiol, etonogestrel, levomefolate, levonorgestrel, lynestrenol, medroxyprogesterone acetate, mestranol, mifepristone, misoprostol, nomegestrol acetate, norelgestromin, norethindrone, noretynodrel, norgestimate, ormeloxifene, segestersone acetate, ulipristal acetate, and any combinations thereof.
  • Gene therapy and cell therapy includes the genetic modification to silence a gene; genetic approaches to directly kill the infected cells; the infusion of immune cells designed to replace most of the patient's own immune system to enhance the immune response to infected cells, or activate the patient's own immune system to kill infected cells, or find and kill the infected cells; and genetic approaches to modify cellular activity to further alter endogenous immune responsiveness against the infection.
  • Examples of dendritic cell therapy include AGS-004.
  • the genome editing system is selected from the group consisting of: a CRISPR/Cas9 system, a zinc finger nuclease system, a TALEN system, a homing endonucleases system, and a meganuclease system.
  • HIV targeting CRISPR/Cas9 systems examples include EBT-101.
  • the HIV antigen include an HIV envelope protein or a portion thereof, gp120 or a portion thereof, a CD4 binding site on gp120, the CD4-induced binding site on gp120, N glycan on gp120, the V2 of gp120, the membrane proximal region on gp41.
  • the immune effector cell is a T cell or an NK cell. In some embodiments, the T cell is a CD4+ T cell, a CD8+ T cell, or a combination thereof. Cells can be autologous or allogeneic.
  • HIV CAR-T examples include VC-CAR-T, anti-CD4 CART cell therapy, autologous hematopoietic stem cells genetically engineered to express a CD4 CAR and the C46 peptide.
  • TCR-T cells are engineered to target HIV derived peptides present on the surface of virus-infected cells.
  • the components of the composition are administered as a simultaneous or sequential regimen.
  • the combination may be administered in two or more administrations.
  • the compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, can be administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that a suitable route may vary with, for example, the condition of the recipient. n certain embodiments, the compounds disclosed can be dosed parenterally. In certain embodiments, the compounds disclosed can be dosed intravenous, subcutaneous, or intramuscular. In certain embodiments, the compounds disclosed are orally bioavailable and can be dosed orally.
  • the compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI , XIa , or XIb , or a pharmaceutically acceptable salt thereof, is administered with a syringe suitable for administration of the compound.
  • the syringe is disposable. In some embodiments, the syringe is reusable.
  • the syringe is pre-filled with the compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI , XIa , or XIb , or a pharmaceutically acceptable salt thereof.
  • the compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, is administered with an auto-injector comprising a syringe.
  • the syringe is disposable. In some embodiments, the syringe is reusable.
  • the syringe is pre-filled with the compound formula I, II, IIIa, IIIb, IV, Va, Vb, VI , VIIa , VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof.
  • the compound such as a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI , XIa , or XIb , or a pharmaceutically acceptable salt thereof, is administered to a subject in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about once a day, at least about once a week, at least about once a month, at least about once every 2 months, at least about once every 3 months, at least about once every 4 months, at least about once every 6 months, or at least about once every 12 months or longer.
  • an effective dosing regimen for a desired period of time or duration, such as at least about once a day, at least about once a week, at least about once a month, at least about once every 2 months, at least about once every 3 months, at least about once every 4 months, at least about
  • the compound is administered on a daily or intermittent schedule. In some embodiments, the compound is administered on a weekly schedule. In some embodiments, the compound is administered on a monthly schedule. In some embodiments, the compound is administered every two months. In some embodiments, the compound is administered every three months. In some embodiments, the compound is administered every four months. In some embodiments, the compound is administered every five months. In some embodiments, the compound is administered every 6 months.
  • the compound such as a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI , XIa , or XIb , or a pharmaceutically acceptable salt thereof, is subcutaneously or intramuscularly administered to a subject at least about once a month.
  • the compound e.g., a compound of formula I, II, IIIa, IIIb, IV, Va, Vb, VI, VIIa, VIIb, VIII, IX, IXa, IXb, X, Xa, Xb, XI , XIa , or XIb , or a pharmaceutically acceptable salt thereof
  • a pharmaceutically acceptable salt thereof is subcutaneously or intramuscularly administered to a subject at least about once every 2 months or at least about once every 3 months, or at least about once every 4 months, or at least about once every 6 months.
  • the compound e.g., a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof
  • a pharmaceutically acceptable salt thereof is subcutaneously administered to a subject at least about once a month.
  • the compound e.g., a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof
  • a pharmaceutically acceptable salt thereof is subcutaneously administered to a subject at least about once every 2 months.
  • the compound e.g., a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof
  • the dosage or dosing frequency of a compound of formula I, II, IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, is adjusted over the course of the treatment, based on the judgment of the administering physician.
  • a compound as disclosed herein e.g., a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb XI, XIa , or XIb
  • a dosage amount can be from 1 mg to 1000 mg of compound.
  • the methods disclosed herein comprise event-driven administration of the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, to the subj ect.
  • the terms “event-driven” and “event-driven administration” refer to administration of the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, (1) prior to an event (e.g., 2 hours, 1 day, 2 days, 5 day, or 7 or more days prior to the event) that would expose the individual to HIV (or that would otherwise increase the individual's risk of acquiring HIV); and/or (2) during an event (or more than one recurring event) that would expose the individual to HIV (or that would otherwise increase the individual's risk of acquiring HIV); and/or (3) after an event (or after the final event in a series of recurring events) that would expose the individual to HIV (or that would otherwise increase the individual's risk of acquiring HIV).
  • an event e.g.,
  • the event driven administration is performed pre-exposure of the subject to the HIV. In some embodiments, the event driven administration is performed post-exposure of the subject to the HIV. In some embodiments, the event driven administration is performed pre-exposure of the subject to the HIV and post-exposure of the subject to the HIV.
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, is administered before exposure of the subject to the HIV.
  • An example of event driven dosing regimen includes administration of the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, within 24 to 2 hours prior to HIV exposure ( e .
  • first sexual activity with sex partner known to be HIV positive, including sexual intercourse) followed by administration of the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt, every 24 hours during the period of exposure ( e .
  • a further example of an event driven dosing regimen includes administration of the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, within 24 hours before HIV exposure (e . g ., sexual activity with sex partner known to be HIV positive), then daily administration during the period of exposure ( e . g ., sexual activity with sex partner known to be HIV positive, including the last sexual intercourse), followed by a last administration approximately 24 hours later after the last exposure (which may be an increased dose, such as a double dose).
  • HIV exposure e . g ., sexual activity with sex partner known to be HIV positive
  • daily administration during the period of exposure (e . g ., sexual activity with sex partner known to be HIV positive, including the last sexual inter
  • the compound of formula I, II, IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, is administered daily.
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof is administered 1 hour to 10 days, 1 hour to 7 days, 1 hour to 5 days, 1 to 72 hours, 1 to 48 hours, 1 to 24 hours, or 12 to 12 hours prior to an event that would increase the individual's risk of acquiring HIV (e.g., prior to sex or other exposure to the HIV virus).
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, is administered within 10 days, 7 days, 5 days, 72 hours, 60 hours, 48 hours, 24 hours, 12 hours, 9 hours, 6 hours, 4 hours, 3 hours, 2 hours, or 1 hour prior to an event that would increase the individual's risk of acquiring HIV (e.g., prior to sex or other exposure to the HIV virus).
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof is administered prior to an event (e . g ., administered prior to the event) that would increase the individual's risk of acquiring HIV, it is administered daily prior to the event (e.g., sexual activity).
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof is administered prior to an event that would increase the individual's risk of acquiring HIV, it is administered one to three times prior to the event.
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, is administered during the time of HIV-exposure.
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb is administered before exposure
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb is administered daily (e.g., as a single dose) during the time of HIV-exposure ( e.g., during the time period of sexual activity with sex partner known to be HIV positive).
  • the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof is administered daily (e.g., for 1 to 7 days) after final exposure to the HIV (e.g., after a period of sexual activity with sex partner known to be HIV positive). In some embodiments, the administration is continued for 1 or 2 days after final exposure to HIV.
  • PrEP and/or PEP can be found, for example, at the clinical trial summary titled “On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men” (Clinical Trial # NCT01473472); the clinical trial summary titled “Prevention of HIV in Île-de-France” (Clinical Trials # NCT03113123), and at Molina, et al. N. Engl. J. Med. 2015, 353:2237-2246 , the disclosure of each of which is incorporated herein by reference in its entirety.
  • methods for reducing the risk of acquiring HIV comprise administration of the compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb , VIII, IX, IXa, IXb , X, Xa, Xb, XI, XIa , or XIb , or a pharmaceutically acceptable salt thereof, in combination with safer sex practices.
  • methods for reducing the risk of acquiring HIV comprise administration to an individual at risk of acquiring HIV. Examples of individuals at high risk for acquiring HIV include, without limitation, an individual who is at risk of sexual transmission of HIV.
  • the reduction in risk of acquiring HIV is at least about 40%, 50%, 60%, 70%, 80%, 90%, or 95%. In some embodiments, the reduction in risk of acquiring HIV is at least about 75%. In some embodiments, the reduction in risk of acquiring HIV is about 80%, 85%, or 90%.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the suspension is a microsuspension. In certain embodiments the suspension is a nanosuspension.
  • formulations suitable for parenteral administration will include one or more excipients.
  • Excipients should be compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof. Examples of suitable excipients are well known to the person skilled in the art of parenteral formulation and may be found, e.g., in Handbook of Pharmaceutical Excipients (eds. Rowe, Sheskey & Quinn), 6th edition 2009 .
  • the active ingredient e . g ., a compound of formula I, II , IIIa , IIIb , IV, Va, Vb, VI, VIIa , VIIb, VIII, IX, IXa, IXb , X, Xa, Xb XI, XIa , or XIb
  • the active ingredient is present as a free acid.
  • the pharmaceutical composition disclosed herein is a parenteral formulation.
  • the formulation is administered subcutaneously to a subject in need thereof.
  • the formulation is administered intramuscularly to a subject in need thereof.
  • a dosage form for oral administration to humans may contain approximately 1 to 1000 mg of active material formulated with an appropriate and convenient amount of carrier material (e . g ., inactive ingredient or excipient material).
  • carrier material e . g ., inactive ingredient or excipient material.
  • the carrier material varies from about 5 to about 95% of the total compositions (weight: weight).
  • compositions of these embodiments may include other agents conventional in the art having regard to the type of composition in question, for example those suitable for oral administration may include flavoring agents.
  • reaction mixture was quenched by addition of ice water slowly and diluted with water ( ⁇ 100 mL) before extracting the product with ethyl acetate (2 x ⁇ 100 mL). After the organic extracts were washed with water ( ⁇ 100-150 mL x 1), the organic fractions were combined, dried over MgSO 4 , filtered, and concentrated. The residue was purified by column chromatography on silica gel eluting 0- ⁇ 70% ethyl acetate in hexane to afford the title compound. MS ( m / z ) 171.74 [M+H-C 4 H 8 ] + .
  • N-(2,4-Difluorobenzyl)-13-hydroxy-1,12-dioxo-1,4,5,7,8,12-hexahydro-3H-2,8-methanopyrido[1,2-d][1,4,7]oxadiazecine-11-carboxamide ( 1 , 15 mg) was separated into its individual enantiomers by preparative SFC chromatography on an AZ-H column using ethanol-TFA co-solvent to provide 1-1 and 1-2.
  • Unpurified 6,6-difluoroazepan-3-amine dihydrochloride (119.9 mg, 0.54 mmol), methyl 3-(benzyloxy)-4-oxo-5-((2,4,6-trifluorobenzyl)carbamoyl)-4H-pyran-2-carboxylate (280.8 mg, 0.63 mmol), and sodium bicarbonate (238.7 mg, 2.84 mmol) were dissolved in methanol (5 mL) and water (1 mL) and the resulting solution was stirred at 55 °C bath for 20 h. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate and water.
  • the partially purified product was dissolved in DMF, filtered, and purified by preparative HPLC (column, Gemini 10 ⁇ C18 110A, AXI/; 250 x 21.2 mm) eluting 30-90% acetonitrile (0.1% TFA) in water (0.1% TFA) over 20 min, and the collected fraction was freeze-dried to afford the title compound.
  • the partially purified product was dissolved in DMF, filtered, and purified by preparative HPLC (column, Gemini 10 ⁇ C18 110A, AXI/; 250 x 21.2 mm) eluting 30-90% acetonitrile (0.1% TFA) in water (0.1% TFA) over 20 min, and the collected fraction was freeze-dried to afford the title compound.
  • Methyl 13-methoxy-1,12-dioxo-1,3,4,5,6,7,8,12-octahydro-2,8-methanopyrido[1,2-a][1,4]diazecine-11-carboxylate 80 mg, 0.25 mmol was dissolved in methanol (3 mL), and 1M NaOH (0.75 mL, 0.75 mmol) was added. After 25 minutes, the reaction was quenched via the addition of 2M HCl and concentrated to dryness.
  • N-(2,4-Difluorobenzyl)-13-methoxy-1,12-dioxo-1,3,4,5,6,7,8,12-octahydro-2,8-methanopyrido[1,2-a][1,4]diazecine-11-carboxamide (43 mg) was separated into its individual enantiomers by preparative SFC chromatography on an IB column using MeOH co-solvent to provide 5c-1 and 5c-2. The separated enantiomers were dissolved in DMF (0.5 mL) with lithium chloride (84 mg, 2.0 mmol) and stirred at 100 °C for 1 h.
  • tert -Butyl (3R)-3-(dibenzylamino)-2-oxo-azepane-1-carboxylate (463 mg, 1.13 mmol) was placed in a round-bottom flask under argon and a solution of dimethyl titanocene (5% in toluene/THF, 16 mL) was added. The mixture was stirred at 80 °C for 75 minutes, cooled to 15 °C, and quenched with aqueous sodium bicarbonate solution. The organic layer was separated, dried over Na 2 SO 4 , filtered, concentrated, and purified by flash column chromatography (hexanes/EtOAc) to provide the title compound.
  • tert -Butyl (3R)-3-(dibenzylamino)-2-methylene-azepane-1-carboxylate 9a , 256 mg, 0.63 mmol
  • isopropanol 3 mL
  • tert -butyl hydroperoxide 5-6M in decane, 214 ⁇ l
  • phenylsilane 78 ⁇ l, 0.63 mmol
  • Tris(dipivaloylmethanato)manganese 34 mg, 0.056 mmol
  • Example 9 Preparation of (7S- and 7R-)-6,6-difluoro-12-hydroxy-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (10-1, 10-2):
  • Example 12 Preparation of N-(2,4-difluorobenzyl)-6-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (13):
  • Example 13 Preparation of (6S,7R)-N-(2,4-difluorobenzyl)-6,12-dihydroxy-6-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and (6R,7S)-N-(2,4-difluorobenzyl)-6,12-dihydroxy-6-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (14-1, 14-2):
  • Example 15 Preparation of (7S)-, and (7R)-N-(2,4-difluorobenzyl)-6,6-difluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (16-1, 16-2):
  • Example 16 Preparation of N-(2,4-difluorobenzyl)-6-fluoro-12-hydroxy-6-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (17-1a) and N-(2,4-difluorobenzyl)-12-hydroxy-6-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (17-1b, 17-2b):
  • Example 17 Preparation of 12-hydroxy-7-methyl-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (18):
  • Example 21 Preparation of racemic- and (R)- or (S)-11-hydroxy-1,10-dioxo-N-(2,4,6-trifluorobenzyl)-1,3,4,5,6,10-hexahydro-2,6-ethanopyrido[1,2-a][1,4]diazocine-9-carboxamide (24 and 24-1):
  • the separated peak 1 was used to make 11-hydroxy-1,10-dioxo-N-(2,4,6-trifluorobenzyl)-1,3,4,5,6,10-hexahydro-2,6-ethanopyndo[1,2-a][1,4]diazocine-9-carboxamide ( 24-1 ). MS ( m / z ) 422.124 [M+H] + .
  • Example 22 Preparation of racemic and (7R)- and (7S)-N-(2,4-difluorobenzyl)-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (25, 25-1, 25-2):
  • Example 23 Preparation of racemic-12-hydroxy-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (26), (7R)-12-hydroxy-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (26-1) and (7S)-12-hydroxy-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (26-2):
  • Racemic 12-(benzyloxy)-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide ( 26a ) was separated by chiral HPLC separation (SFC chromatography on an IB 4.6X100mm 5mic column using MeOH(20) as co-solvent) to obtain compounds (7R)-12-(Benzyloxy)-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide ( 26a-1 ) and (7S)-12-(benzyloxy)-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,
  • N-(2,4-difluorobenzyl)-7-hydroxy-6,8,15-trioxo-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide ( 27 ) was prepared followed by same procedure as compound 26, starting from 7-(benzyloxy)-N-(2,4-difluorobenzyl)-6,8,15-trioxo-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide (11mg).
  • N-(2,4-Difluorobenzyl)-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4,7]triazonine-10-carboxamide ( 30 ) was synthesized from 1,4-diazepan-6-amine (75.1 mg, 0.652 mmol) and methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-4H-pyran-2-carboxylate (140 mg, 0.326 mmol) followed a similar procedure as compound 28. MS (m / z) 405.183 [M+H] + .
  • Example 28 Preparation of 5-acetyl-N-(2,4-difluorobenzyl)-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4,7]triazonine-10-carboxamide (31):
  • N-(2,4-Difluorobenzyl)-12-hydroxy-5-(methylsulfonyl)-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4,7]triazonine-10-carboxamide ( 32 ) was synthesized from 12-(benzyloxy)-N-(2,4-difluorobenzyl)-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4,7]triazonine-10-carboxamide (26 mg, 0.053 mmol) following the same procedure as used to prepare compound 31 , and using methanesulfonyl chloride (9 mg, 0.079 mmol).
  • N-(2,4-Difluorobenzyl)-12-hydroxy-5-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4,7]triazonine-10-carboxamide ( 33 ) was synthesized from 12-(benzyloxy)-N-(2,4-difluorobenzyl)-5-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4,7]triazonine-10-carboxamide ( 33a ) follow the same debenzylation conditions as those used to prepare compound 30.
  • N-(2,4-Difluorobenzyl)-12-hydroxy-5-isopropyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4,7]triazonine-10-carboxamide ( 34 ) was synthesized from 12-(benzyloxy)-N-(2,4-difluorobenzyl)-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4,7]triazonine-10-carboxamide (24 mg, 0.049 mmol) following a similar procedure as that used to prepare compound 33, using 2-iodopropane (12.38 mg, 0.073 mmol).
  • N-(2,4-Difluorobenzyl)-7-hydroxy-6,8-dioxo-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide ( 36 ) was synthesized from methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-4H-pyran-2-carboxylate (30 mg, 0.07 mmol) and 2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-amine follow the same procedure as that used to prepare compound 28.
  • Example 37 Preparation of (4R,7S,8S)- and (4S,7R,8R)-13-hydroxy-1,12-dioxo-N-(2,4,6-trifluorobenzyl)-1,3,4,5,6,7,8,12-octahydro-2,8:4,7-dimethanopyrido[1,2-a][1,4]diazecine-11-carboxamide (40-1, 40-2):
  • rel -(1R,4S,6R)-2-Azabicyclo[4.2.1]nonan-4-amine ( 40f ) was synthesized from rel-tert -butyl ((1R,4S,6S)-3-oxo-2-azabicyclo[4.2.1]nonan-4-yl)carbamate ( 40c ) analogously to the synthesis of 2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-amine ( 36c ) from tert -butyl (2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)carbamate ( 36a ).
  • Example 38 Preparation of (4S,7R,8S)- and (4R,7S,8R)-13-hydroxy-1,12-dioxo-N-(2,4,6-trifluorobenzyl)-1,3,4,5,6,7,8,12-octahydro-2,8:4,7-dimethanopyrido[1,2-a][1,4]diazecine-11-carboxamide (41-1 and 41-2):
  • Example 39a Preparation of N-(2,4-difluorobenzyl)-5-hydroxy-4,6-dioxo-1,1a,2,4,6,10,11,11a-octahydro-3,10-methanocyclopropa[f]pyrido[1,2-a][1,4]diazonine-7-carboxamide (42-1):
  • Example 39b Preparation of (1aS,10R,11aS)-N-(2,4-difluorobenzyl)-5-hydroxy-4,6-dioxo-1,1a,2,4,6,10,11,11a-octahydro-3,10-methanocyclopropa[f]pyrido[1,2-a][1,4]diazonine-7-carboxamide (42-2):
  • Example 40 Preparation of (7S)-2,4,6-trifluorobenzyl 12-methoxy-1,11-dioxo-1,3,4,5,6,11-hexahydro-7l3-2,7-methanopyrido[2,1-c][1,4]diazonine-10-carboxylate and (7R) -2,4,6-trifluorobenzyl 12-methoxy-1,11-dioxo-1,3,4,5,6,11-hexahydro-7l3-2,7-methanopyrido[2,1-c][1,4]diazonine-10-carboxylate (43-1, 43-2):
  • Example 41 Preparation of (8R,Z)-N-(2,4-difluorobenzyl)-13-hydroxy-1,12-dioxo-1,3,4,7,8,12-hexahydro-2,8-methanopyrido[1,2- a ][1,4]diazecine-11-carboxamide and (8S,Z)-N-(2,4-difluorobenzyl)-13-hydroxy-1,12-dioxo-1,3,4,7,8,12-hexahydro-2,8-methanopyrido[1,2- a ][1,4]diazecine-11-carboxamide (44-1 and 44-2):
  • Example 42 Preparation of (12S)-1-chloro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide and (12R)-1-chloro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide (45-1 and 45-2):
  • Example 43 Preparation of (12S)-4-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide and (12R)-4-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide (46-1 and 46-2):
  • Example 44 Preparation of (7R)-N-(2,4-difluorobenzyl)-12-hydroxy-1,11-dioxo-1,6,7,11-tetrahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and (7S)-N-(2,4-difluorobenzyl)-12-hydroxy-1,11-dioxo-1,6,7,11-tetrahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (47-1 and 47-2):
  • Example 45 Preparation of (12S)-2-chloro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide and (12R)-2-chloro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide (48-1 and 48-2):
  • Example 46 Preparation of (12S)-2-chloro-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-dioxo-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide and (12R)-2-chloro-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-dioxo-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e] pyrido [1,2-a][1,4]diazonine-9-carboxamide (49-1 and 49-2):
  • the title compounds were prepared in a manner analogous to 43-1 and 43-2, using 7-chloro-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one in place of 6-fluoro-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one, and methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-4H-pyran-2-carboxylate in place of methyl 3-(benzyloxy)-4-oxo-5-((2,4,6-trifluorobenzyl)carbamoyl)-4H-pyran-2-carboxylate.
  • Example 47 Preparation of (12S)-2,3-difluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide and (12R)-2,3-difluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide (50-1 and 50-2):
  • Example 48 Preparation of (7S)-N-(3-chloro-2,4-difluorobenzyl)-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (51):
  • Example 49 Preparation of ( 3R , 7S )- N -(2,4-difluorobenzyl)-12-hydroxy-3-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide, ( 3S , 7R )- N -(2,4-difluorobenzyl)-12-hydroxy-3-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide, ( 3R , 7R )- N -(2,4-difluorobenzyl)-12-hydroxy-3-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a
  • the title compounds were prepared in a manner analogous to 43c, using 7-methylazepan-2-one ( 52a ) in place of 6-fluoro-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one. Diastereoisomers 52b-1 and 52b-2 were separated via silica gel column chromatography. 52b-1: MS (m/z) 242.73 [M+H] + ; 52b-2: MS (m/z) 242.73 [M+H] + .
  • Benzyl ( (Z) -7-methyl-2-oxoazepan-3-yl)carbamate was separated into its individual enantiomers by preparative SFC chromatography on an AZ-H column using ethanoltrifluoroacetic acid co-solvent to provide benzyl (( 3S,7R )-7-methyl-2-oxoazepan-3-yl)carbamate and benzyl ( 3R , 7S )-7-methyl-2-oxoazepan-3-yl)carbamate ( 52c-1a and 52c-1b ).
  • Benzyl (( 3R, 7R )-7-methyl-2-oxoazepan-3-yl)carbamate and benzyl ( 3S, 7S )-7-methyl-2-oxoazepan-3-yl)carbamate ( 52c-2a , and 52c-2b ) were prepared in a similar manner from (( E )-7-methyl-2-oxoazepan-3-yl)carbamate ( 52b-2 ).
  • the crude amine was dissolved in ethanol (5 mL), and 10% palladium on carbon (38.8 mg) was added. The resulting mixture was stirred under H 2 atmosphere for 1 h. The mixture was filtered through celite, the pad washed with ethanol, and the filtrate concentrated to get the crude diamine.
  • Example 50a Preparation of ( 4R , 7S )-N-(2,4-difluorobenzyl)-4-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and ( 4S,7S )-N-(2,4-difluorobenzyl)-4-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (53-1 and 53-2) (SDS1, diastereomer 1):
  • 53b-1 MS ( m / z ) 397.3 [M+H] + ; 53b-2: MS ( m / z ) 397.0 [M+H] + .
  • Example 50b Preparation of ( 4S , 7R )-N-(2,4-difluorobenzyl)-4-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and ( 4R,7S )-N-(2,4-difluorobenzyl)-4-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (53-3 and 53-4):
  • the title compound was prepared from (7S)-12-methoxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxylic acid ( 51a ) and (2-fluoro-3-methoxyphenyl)methanamine according to the method described for compound 51. MS ( m / z ) 416.2 [M+H] + .
  • Example 52 Preparation of ( 12S )-2-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e]pyrido[1,2-a][1,4]diazonine-9-carboxamide and ( 12R )-2-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorobenzyl)-6,8,13,14-tetrahydro-12H-5,12-methanobenzo[e] pyrido [1 ,2-a] [1,4]diazonine-9-carboxamide (55-1 and 55-2):
  • Example 53a ( 5S,7S )-N-(2,4-difluorobenzyl)-5-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and ( 5R,7S )-N-(2,4-difluorobenzyl)-5-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (56-1 and 56-2):
  • the title compounds were synthesized in a manner similar to 53-1 and 53-2, using benzyl (S)-3-(((benzyloxy)carbonyl)amino)-5-oxoazepane-1-carboxylate ( 53b-2 ) in place of benzyl (S)-3-(((benzyloxy)carbonyl)amino)-6-oxoazepane-1-carboxylate ( 53b-1 ), and separating the stereoisomers as the benzyl protected alcohol instead of prior to amide coupling.
  • Example 53b ( 5S,7R )-N-(2,4-difluorobenzyl)-5-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and ( 5R,7R )-N-(2,4-difluorobenzyl)-5-fluoro-12-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2, 7- methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (56-3 and 56-4):
  • Example 54 Preparation of (7'S)-N-(2,4-difluorobenzyl)-12'-hydroxy-1',11'-dioxo-1',4',5',11'-tetrahydro-3'H,7'H-spiro[cyclopropane-1,6'-[2,7]methanopyrido[1,2-a][1,4]diazonine]-10'-carboxamide and (7'R)-N-(2,4-difluorobenzyl)-12'-hydroxy-1',11'-dioxo-1',4',5',11'-tetrahydro-3'H,7'H-spiro[cyclopropane-1,6'-[2,7]methanopyrido[1,2-a][1,4]diazonine]-10'-carboxamide (57-1 and 57-2):
  • Example 56 Preparation of (7S)-12-hydroxy-7-methyl-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and (7R)-12-hydroxy-7-methyl-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (59-1 and 59-2):
  • Example 57a Preparation of (6S,7R)-N-(2,4-difluorobenzyl)-6-fluoro-12-hydroxy-6-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (60-1):
  • the title compound was prepared in a manner similar to 13a using benzyl (3R,4R)-3-(((benzyloxy)carbonyl)amino)-4-hydroxy-4-methylazepane-1-carboxylate ( 60a-2 ) instead of 12-(benzyloxy)-N-(2,4-difluorobenzyl)-6-hydroxy-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide ( 12a ).
  • MS ( m / z ) 415.78 [M+H] + .
  • the structure was confirmed by X-ray Crystallography.
  • Benzyl (3R,4S)-3-(((benzyloxy)carbonyl)amino)-4-fluoro-4-methylazepane-1-carboxylate 60b-2 , 110 mg, 0.265 mmol
  • Palladium hydroxide on carbon 37.3 mg, 0.05 mmol, 20% Pd weight
  • the mixture was sparged under a hydrogen atmosphere (1 atm, balloon). The mixture was stirred vigorously for 1 day and sparged under an argon atmosphere.
  • Example 57b Preparation of (6S, 7S )-N-(2,4-difluorobenzyl)-6-fluoro-12-hydroxy-6-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and (6R, 7S )-N-(2,4-difluorobenzyl)-6-fluoro-12-hydroxy-6-methyl-1,11-dioxo-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (60-2 and 60-3):
  • the title compounds were prepared in a manner similar to 60-1 using benzyl ( 3S,4R ) 3-(((benzyloxy)carbonyl)amino)-4-hydroxy-4-methylazepane-1-carboxylate - or benzyl ( 3S,4S )-3-(((benzyloxy)carbonyl)amino)-4-hydroxy-4-methylazepane-1-carboxylate ( 60a-3 or 60a-4 ) instead of benzyl (3R,4R)-3-(((benzyloxy)carbonyl)amino)-4-hydroxy-4-methylazepane-1-carboxylate ( 60a-2 ).
  • Example 58 Preparation of ( 6S , 7S )-6-fluoro-12-hydroxy-6-methyl-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide and (6R, 7S )-6-fluoro-12-hydroxy-6-methyl-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide (61-1 and 61-2):
  • the title compounds were prepared in a similar manner to 60-2 and 60-3 using methyl 3-(benzyloxy)-4-oxo-5-((2,4,6-trifluorobenzyl)carbamoyl)-4H-pyran-2-carboxylate instead of methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-4H-pyran-2-carboxylate.
  • Example 60 Preparation of (13S)-4-hydroxy-3,5-dioxo-N-(2,4,6-trifluorobenzyl)-3,5,8,13-tetrahydro-7H-6,13-methanobenzo[g]pyrido[1,2-a][1,4]diazonine-2-carboxamide and (13R)-4-hydroxy-3,5-dioxo-N-(2,4,6-trifluorobenzyl)-3,5,8,13-tetrahydro-7H-6,13-methanobenzo[g]pyrido[1,2-a][1,4]diazonine-2-carboxamide (63-1 and 63-2):

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP22179180.9A 2019-03-22 2020-03-20 Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung Pending EP4122537A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962822703P 2019-03-22 2019-03-22
US201962948697P 2019-12-16 2019-12-16
EP20719849.0A EP3938047B1 (de) 2019-03-22 2020-03-20 Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung
PCT/US2020/023819 WO2020197991A1 (en) 2019-03-22 2020-03-20 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP20719849.0A Division EP3938047B1 (de) 2019-03-22 2020-03-20 Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung

Publications (1)

Publication Number Publication Date
EP4122537A1 true EP4122537A1 (de) 2023-01-25

Family

ID=70293100

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20719849.0A Active EP3938047B1 (de) 2019-03-22 2020-03-20 Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung
EP22179180.9A Pending EP4122537A1 (de) 2019-03-22 2020-03-20 Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20719849.0A Active EP3938047B1 (de) 2019-03-22 2020-03-20 Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung

Country Status (28)

Country Link
US (4) US11084832B2 (de)
EP (2) EP3938047B1 (de)
JP (3) JP7265647B2 (de)
KR (2) KR20240151256A (de)
CN (2) CN119462659A (de)
AU (3) AU2020245350B2 (de)
CL (2) CL2021002444A1 (de)
CO (1) CO2021012319A2 (de)
CR (2) CR20210486A (de)
DK (1) DK3938047T3 (de)
DO (2) DOP2021000195A (de)
ES (1) ES2927041T3 (de)
HR (1) HRP20221074T1 (de)
HU (1) HUE059677T2 (de)
IL (1) IL286328A (de)
LT (1) LT3938047T (de)
MX (2) MX2021011394A (de)
MY (1) MY201239A (de)
PE (1) PE20212074A1 (de)
PH (1) PH12021500040A1 (de)
PL (1) PL3938047T3 (de)
PT (1) PT3938047T (de)
SG (1) SG11202109650XA (de)
SI (1) SI3938047T1 (de)
TW (2) TWI745900B (de)
UA (1) UA127822C2 (de)
WO (1) WO2020197991A1 (de)
ZA (1) ZA202107015B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6317817B2 (ja) 2013-07-25 2018-04-25 コンヴィーダ ワイヤレス， エルエルシー エンドツーエンドｍ２ｍサービス層セッション
SG11202011386QA (en) 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
AU2019277548B2 (en) 2018-05-31 2023-12-14 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative
JP2021530523A (ja) * 2018-07-16 2021-11-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのカプシド阻害剤
WO2020068251A1 (en) 2018-09-27 2020-04-02 Convida Wireless, Llc Sub-band operations in unlicensed spectrums of new radio
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
WO2021173522A1 (en) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
KR20230079137A (ko) * 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
CN114426540B (zh) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用
TW202227445A (zh) * 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
CN116745292A (zh) * 2021-01-19 2023-09-12 吉利德科学公司 经取代的吡啶并三嗪化合物及其用途
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
WO2023018913A1 (en) * 2021-08-11 2023-02-16 Merck Sharp & Dohme Llc Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza
WO2023081637A1 (en) 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
FI4445900T3 (fi) 2021-12-03 2025-08-05 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
US12378202B2 (en) 2021-12-23 2025-08-05 Springworks Therapeutics, Inc. Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4547659A1 (de) 2022-07-01 2025-05-07 Gilead Sciences, Inc. Therapeutische verbindungen zur prophylaktischen oder therapeutischen behandlung einer hiv-virus-infektion
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250120989A1 (en) * 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202525289A (zh) * 2023-12-22 2025-07-01 美商基利科學股份有限公司 用於製備治療性化合物之方法及中間物
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2006015261A2 (en) 2004-07-27 2006-02-09 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
US20100143301A1 (en) 2008-12-09 2010-06-10 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2010130034A1 (en) 2009-05-15 2010-11-18 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2012003498A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
WO2012003497A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Napht- 2 -ylacetic acid derivatives to treat aids
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
WO2013006792A1 (en) 2011-07-07 2013-01-10 Pharmaresources (Shanghai) Co., Ltd. Antiviral compounds
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
WO2013159064A1 (en) 2012-04-20 2013-10-24 Gilead Sciences, Inc. Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
WO2014100323A1 (en) 2012-12-21 2014-06-26 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221380A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
WO2014200880A1 (en) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2016094198A1 (en) * 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016161382A1 (en) * 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017106346A2 (en) 2015-12-15 2017-06-22 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
WO2018145021A1 (en) 2017-02-06 2018-08-09 Gilead Sciences, Inc. Atazanavir (atv) analogues for treating hiv infections

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4537885A (en) 1983-02-10 1985-08-27 Ciba Geigy Corporation Certain benzazocinone and benzazoninone derivatives
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
AU2001282941C1 (en) 2000-07-21 2016-12-22 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
EP1866313A1 (de) * 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv-integrasehemmer
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
EP1910363A4 (de) 2005-08-04 2010-05-26 Glaxosmithkline Llc Hiv-integrasehemmer
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
AU2006306355A1 (en) 2005-10-27 2007-05-03 Merck & Co., Inc. HIV integrase inhibitors
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
AR061838A1 (es) 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010506913A (ja) 2006-10-18 2010-03-04 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤
EA021463B1 (ru) 2007-06-29 2015-06-30 Джилид Сайэнс, Инк. Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CN101918372B (zh) 2008-01-08 2014-03-26 默沙东公司 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2280968A2 (de) 2008-03-24 2011-02-09 Medivation Technologies, Inc. Pyrido[3,4-b]indole und anwendungsverfahren
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
WO2009154870A1 (en) 2008-05-05 2009-12-23 Merck & Co., Inc. Hiv integrase inhibitors
US8426405B2 (en) 2008-07-02 2013-04-23 Avexa Limited Thiazopyrimidinones and uses thereof
ES2448766T3 (es) 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
SG192550A1 (en) 2008-07-25 2013-08-30 Viiv Healthcare Co Chemical compounds
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
US8183372B2 (en) 2008-07-25 2012-05-22 Shionogi & Co., Ltd. Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
PT2313111E (pt) 2008-08-01 2013-12-05 Ventirx Pharmaceuticals Inc Formulações de agonista de receptor do tipo toll e seus usos
EP2349276B1 (de) 2008-10-06 2019-11-27 Merck Sharp & Dohme Corp. Hiv-integrasehemmer
EP2376080B1 (de) 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthese von carbamoylpyridon-hiv-integrase-hemmern und zwischenprodukte
US20120022045A1 (en) 2009-01-28 2012-01-26 Shankar Venkatraman Bridged compounds as hiv integrase inhibitors
US8673307B1 (en) 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
RS57244B1 (sr) 2009-06-15 2018-07-31 Shionogi & Co Supstituisani policiklički derivati karbamoilpiridona
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
PL2467377T3 (pl) 2009-08-18 2017-10-31 Ventirx Pharmaceuticals Inc Podstawione benzoazepiny jako modulatory receptora toll-podobnego
WO2011022509A2 (en) 2009-08-18 2011-02-24 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20120220571A1 (en) 2009-08-26 2012-08-30 Wai John S Hiv integrase inhibitors
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
WO2011049825A1 (en) 2009-10-22 2011-04-28 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
PH12012501689A1 (en) 2010-02-26 2012-11-05 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv intergrase inhibitor
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
ES2608377T3 (es) 2010-08-05 2017-04-10 Shionogi & Co., Ltd. Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
BR112013007678A2 (pt) 2010-10-01 2017-07-04 Ventirx Pharmaceuticals Inc método para tratamento de doenças alérgicas
MX340290B (es) 2010-10-01 2016-07-04 Ventirx Pharmaceuticals Inc Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación.
AU2011320651A1 (en) 2010-10-29 2013-05-02 Merck Canada Inc. HIV integrase inhibitors
US8835411B2 (en) * 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
US9718796B2 (en) 2011-01-12 2017-08-01 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
LT3590928T (lt) 2011-04-08 2021-08-25 Janssen Sciences Ireland Unlimited Company Pirimidino dariniai, skirti virusinės infekcijos gydymui
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
US9783594B2 (en) 2011-05-17 2017-10-10 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
US8916575B2 (en) 2011-05-18 2014-12-23 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
DK2744810T4 (da) 2011-08-16 2023-11-20 Gilead Sciences Inc Tenofovir-alafenamid-hemifumarat
KR102033802B1 (ko) 2011-10-07 2019-10-17 길리애드 사이언시즈, 인코포레이티드 항-바이러스 뉴클레오티드 유사체의 제조 방법
BR112014008896A2 (pt) 2011-10-12 2017-04-18 Shionogi & Co derivado de piridona policíclico tendo atividade inibidora de integrase
CA2858716C (en) 2011-12-08 2021-10-12 Peter D. Kwong Neutralizing antibodies to hiv-1 and their use
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
BR112014019699B1 (pt) 2012-02-08 2021-12-07 Janssen Sciences Ireland Uc Derivados de piperidino-pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende
WO2013142324A1 (en) 2012-03-23 2013-09-26 Usa, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
KR20150034733A (ko) 2012-06-25 2015-04-03 선파워 코포레이션 태양광 모듈 어레이를 위한 브레이스
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
US20150166520A1 (en) 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
BR112015002524B1 (pt) 2012-08-10 2021-11-03 Janssen Sciences Ireland Uc Derivados de alquilpirimidina, composição farmacêutica que os compreende e uso dos mesmos
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
SI2906563T1 (en) 2012-10-10 2018-06-29 Janssen Sciences Ireland Uc Derivatives of pyrrolo (3,2-d) pyrimidine for the treatment of viral infections and other diseases
CN118955699A (zh) 2012-10-18 2024-11-15 洛克菲勒大学 广泛中和性抗hiv抗体
DE102012220513B4 (de) 2012-11-12 2023-02-16 Bayerische Motoren Werke Aktiengesellschaft Verfahren und Vorrichtung zur Herstellung eines Druckgussteils
MY171115A (en) 2012-11-16 2019-09-26 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
US9951106B2 (en) 2012-12-04 2018-04-24 University Of Maryland, Baltimore Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EP2986291B1 (de) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridonderivatverbindungen und verwendungen davon als hiv-integrase-hemmer
ES2656696T3 (es) 2013-05-17 2018-02-28 Merck Sharp & Dohme Corp. Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del VIH
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
NO2865735T3 (de) 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015048462A1 (en) 2013-09-27 2015-04-02 Duke University Human monoclonal antibodies
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015117008A2 (en) 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
NO2717902T3 (de) 2014-06-20 2018-06-23
WO2016014484A1 (en) 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers
WO2016027879A1 (ja) 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
JP2017526748A (ja) 2014-08-27 2017-09-14 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤として使用するためのイミダゾ［１，２−ａ］ピリジン誘導体
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
NZ733125A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
BR112017013491A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de pirimidina fundida para o tratamento de hiv
WO2016149710A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof
HRP20200583T1 (hr) 2015-03-20 2020-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protutijela koja neutraliziraju gp120 i njihova upotreba
EP3285582B1 (de) 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphatsubstituierte chinolizinderivate als hiv-integrase-hemmer
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
WO2017087256A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2017096221A1 (en) 2015-12-02 2017-06-08 The Rockefeller University Bispecific anti-hiv broadly neutralizing antibodies
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
EP3383430A4 (de) 2015-12-02 2019-12-18 Agenus Inc. Antikörper und verfahren zur verwendung davon
WO2017096182A1 (en) 2015-12-03 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
CN107022027B (zh) 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
CN107033241B (zh) 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
WO2017223280A2 (en) 2016-06-23 2017-12-28 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
BR112018071678B1 (pt) 2016-08-19 2021-01-26 Gilead Sciences, Inc. compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
AU2017367714B2 (en) 2016-12-02 2020-11-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
EP3573984A4 (de) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. Als hiv-integrase-inhibitoren nützliche, substituierte chinolizinderivate
WO2018237148A1 (en) 2017-06-21 2018-12-27 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
IL273428B2 (en) 2017-09-22 2023-09-01 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019087016A1 (en) 2017-10-30 2019-05-09 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
EP3752042B1 (de) 2018-02-13 2024-07-10 Cool Vapor Solutions Zusammensetzungen zur befeuchtung und kühlung von gasströmen
US11413292B2 (en) 2018-02-15 2022-08-16 Merck, Sharp & Dohme LLC Tricyclic heterocycle compounds useful as HIV integrase inhibitors
JP2021522254A (ja) 2018-04-27 2021-08-30 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
AU2019277548B2 (en) 2018-05-31 2023-12-14 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative
SG11202011386QA (en) 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
CN112204029B (zh) 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 治疗性化合物
ES2989103T3 (es) 2018-06-05 2024-11-25 Merck Sharp & Dohme Llc Compuestos de heterociclo tricíclico útiles como inhibidores de la integrasa del VIH
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020004443A1 (ja) 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
MX2021004182A (es) 2018-10-10 2021-09-08 Janssen Biopharma Inc Inhibidores macrocíclicos de endonucleasa de la gripe.
MY207622A (en) 2018-10-22 2025-03-06 Univ Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
CN113795491B (zh) 2019-04-30 2024-09-03 上海拓界生物医药科技有限公司 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CA3142030A1 (en) 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Compounds useful to treat influenza virus infections
TW202120510A (zh) 2019-11-13 2021-06-01 大陸商上海拓界生物醫藥科技有限公司 新型四環雜環化合物及其藥物用途
JPWO2021107066A1 (de) 2019-11-28 2021-06-03
US20230058677A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Polycyclic pyridopyrazine derivative
WO2021173522A1 (en) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
TW202227445A (zh) * 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
JP2024507788A (ja) 2021-02-16 2024-02-21 メルク・シャープ・アンド・ドーム・エルエルシー Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2006015261A2 (en) 2004-07-27 2006-02-09 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
US20100143301A1 (en) 2008-12-09 2010-06-10 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2010130034A1 (en) 2009-05-15 2010-11-18 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
WO2012003498A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
WO2012003497A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Napht- 2 -ylacetic acid derivatives to treat aids
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
WO2013006792A1 (en) 2011-07-07 2013-01-10 Pharmaresources (Shanghai) Co., Ltd. Antiviral compounds
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
WO2013159064A1 (en) 2012-04-20 2013-10-24 Gilead Sciences, Inc. Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
WO2014100323A1 (en) 2012-12-21 2014-06-26 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221356A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221380A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
WO2014200880A1 (en) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2016094198A1 (en) * 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016161382A1 (en) * 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017106346A2 (en) 2015-12-15 2017-06-22 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
WO2018145021A1 (en) 2017-02-06 2018-08-09 Gilead Sciences, Inc. Atazanavir (atv) analogues for treating hiv infections

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FOSTER: "Deuterium Isotope Effects in Studies of Drug Metabolism", TRENDS PHARMACOL. SCI., vol. 5, no. 12, 1984, pages 524 - 527, XP025943358, DOI: 10.1016/0165-6147(84)90534-0
HURT ET AL., HIV/AIDS CID, vol. 58, 2014, pages 423 - 431
MOLINA ET AL., N. ENGL. J. MED., vol. 353, 2015, pages 2237 - 2246
ORGANIC PREPARATION AND PROCEDURES INTERNATIONAL, vol. 34, no. 4, 2002, pages 405 - 415
PALELLA ET AL., N. ENGL. JMED., vol. 338, 1998, pages 853 - 860
RICHMAN, D. D., NATURE, vol. 410, 2001, pages 995 - 1001
TANG ET AL., DRUGS, vol. 72, no. 9, 2012, pages e1 - e25

Also Published As

Publication number Publication date
SG11202109650XA (en) 2021-10-28
CN113874079B (zh) 2024-11-08
AU2025205458A1 (en) 2025-07-31
CO2021012319A2 (es) 2021-10-20
KR20240151256A (ko) 2024-10-17
KR102714084B1 (ko) 2024-10-08
CL2022003688A1 (es) 2023-07-28
JP2022526895A (ja) 2022-05-27
US20200317689A1 (en) 2020-10-08
MX2021011394A (es) 2021-10-13
JP2023033640A (ja) 2023-03-10
US11548902B1 (en) 2023-01-10
TWI745900B (zh) 2021-11-11
UA127822C2 (uk) 2024-01-10
HRP20221074T1 (hr) 2022-11-11
NZ781550A (en) 2024-08-30
EP3938047A1 (de) 2022-01-19
CR20240238A (es) 2024-08-12
AU2020245350A1 (en) 2021-11-18
MX2024015459A (es) 2025-02-10
PE20212074A1 (es) 2021-10-26
LT3938047T (lt) 2022-10-10
BR112021018827A2 (pt) 2021-11-23
US11084832B2 (en) 2021-08-10
CN119462659A (zh) 2025-02-18
HUE059677T2 (hu) 2022-12-28
US20250115619A1 (en) 2025-04-10
CA3128961A1 (en) 2020-10-01
ES2927041T3 (es) 2022-11-03
MY201239A (en) 2024-02-13
DK3938047T3 (da) 2022-09-05
WO2020197991A1 (en) 2020-10-01
SI3938047T1 (sl) 2022-10-28
AU2023204700B2 (en) 2025-04-24
EP3938047B1 (de) 2022-06-22
CR20210486A (es) 2021-12-07
DOP2021000195A (es) 2021-10-31
KR20210142711A (ko) 2021-11-25
US20230027019A1 (en) 2023-01-26
CL2021002444A1 (es) 2022-07-08
JP2025013503A (ja) 2025-01-24
DOP2022000240A (es) 2022-11-30
JP7265647B2 (ja) 2023-04-26
PL3938047T3 (pl) 2022-11-07
IL286328A (en) 2021-10-31
US12227520B2 (en) 2025-02-18
JP7710476B2 (ja) 2025-07-18
AU2023204700A1 (en) 2023-08-10
AU2020245350B2 (en) 2023-04-20
CN113874079A (zh) 2021-12-31
PT3938047T (pt) 2022-10-03
TW202204356A (zh) 2022-02-01
PH12021500040A1 (en) 2022-06-06
ZA202107015B (en) 2024-04-24
TWI873387B (zh) 2025-02-21
TW202102499A (zh) 2021-01-16
US20230203061A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
EP3938047B1 (de) Verbrückte tricyclische carbamoylpyridonverbindungen und ihre pharmazeutische verwendung
EP4321217A2 (de) Substituierte pyridotriazinverbindungen und verwendungen davon
HK40085013A (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
HK40067156B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
HK40067156A (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CA3128961C (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
BR122024022984A2 (pt) Compostos de carbamoilpiridona tricíclica em ponte, composição farmacêutica e kit compreendendo os mesmos, e seu uso farmacêutico
BR112021018827B1 (pt) Compostos de carbamoilpiridona tricíclica em ponte, composições farmacêuticas que os compreendem, e usos dos mesmos
BR122023018482B1 (pt) Compostos de carbamoilpiridona tricíclica em ponte, composições que os compreendem, e usos dos mesmos
HK40061199A (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
EA048888B1 (ru) Мостиковые трициклические карбамоилпиридоновые соединения и их фармацевтическое применение
TW202544011A (zh) 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
HK40104840A (en) Substituted pyridotriazine compounds and uses thereof
HK40094146A (en) Substituted pyridotriazine compounds and uses thereof
HK40094146B (en) Substituted pyridotriazine compounds and uses thereof
HK40061199B (zh) 桥连三环氨基甲醯基吡啶酮化合物及其药学用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3938047

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085013

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230725

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR